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Introduction 
 
General 
 
Angiotensin II (Ang II), an octapeptide that is generated by cleavage from 
angiotensinogen through an action of two different peptides, renin and angiotensin-
converting enzyme (ACE), is the potent effector peptide of the hormonal renin-
angiotensin system (RAS) (Skeggs et al., 1956). Ang II exerts a wide range of 
physiological actions on the cardiovascular, renal and endocrine systems. The 
peptide plays an important role in the regulation of blood pressure and the 
maintenance of volume and fluid homeostasis. The classical actions of Ang II include 
vasoconstriction, facilitation of sympathetic neurotransmission and water and sodium 
retention, directly or indirectly via aldosterone secretion from the adrenal gland. In the 
last three decades, evidence has accumulated that Ang II can be formed in various 
tissues, such as the brain, the kidney, the adrenal gland, the heart and the blood 
vessels, independently of the hormonal RAS (Campbell, 1987; Dzau, 1988; Unger et 
al., 1988). 
Over the last few years, the classification of angiotensin receptors and our 
knowledge about their functions, distribution, expression and regulation have been 
extensively expanded after the development of selective angiotensin receptor 
ligands. Ang II binds at least to two receptor subtypes, referred to as the AT1 and the 
AT2 receptor. Both receptors have been cloned; they are seven transmembrane 
glycoproteins with only 32-34 % homology (de Gasparo et al., 2000; Kambayashi et 
al., 1993; Murphy et al., 1991). In rodents, but not in humans, the AT1 receptor exists 
as two isoforms, designated as AT1a and AT1b. 
All classical peripheral actions of Ang II are mediated by the AT1 receptor. In 
addition, this receptor subtype may also initiate proliferation, hypertrophy and growth 
in various tissues. Although numerous findings have demonstrated that Ang II via the 
AT2 receptor acts as a modulator of biological programs involved in embryonic 
development, tissue regeneration and protection, and initiates processes leading to 
programmed cell death (apoptosis), the physiological and pathophysiological role of 
the AT2 receptor is still poorly understood (Unger, 1999 ). 
In the recent years, it has become more evident that the RAS plays a major role in 
the development and the maintenance of arterial hypertension. However, Ang II has 
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also been implicated in cardiovascular and renal pathology, such as cardiac left 
ventricular hypertrophy, heart failure, post-infarction remodeling, vascular neointima 
formation and atherosclerosis (Timmermans et al., 1993). 
 
Historical background on the RAS 
 
The first evidence of the existence of the RAS and its role in the regulation of blood 
pressure came from the discovery of a pressor principle in 1898 when Tigerstedt and 
Bergmann injected rabbits with other rabbit kidney extracts. In 1934, Goldblatt and 
the co-workers rediscovered the importance of renin for blood pressure regulation. 
They also were able to demonstrate a relationship between renin secretion and renal 
ischemia (Goldblatt et al., 1934). Within the following years, renin was biologically 
characterized. In 1941, Page et al identified the renin substrate, angiotensinogen, as 
a plasma protein and interpreted the RAS as a functional unit. At that time, 
angiotensin I (Ang I) was considered as the principle hormone causing a direct 
increase in blood pressure. In 1956, Skeggs et al discovered ACE in the lung, which 
converts Ang I into Ang II. Ang II was later identified, synthesized isolated and shown 
to be an octapeptide (Rittel et al., 1957). The angiotensin receptors were identified as 
a functional entity in 1970 (Lin & Goodfriend, 1970). It was not reported until the end 
of the 1980s that there are at least two Ang II receptor subtypes: AT1 and AT2 
receptors. During the last decades, the studies of the RAS have focused on the wide 
spectrum of Ang II actions in target tissues, the biological activities of angiotensin-
derived peptides and the expression, regulation and function of angiotensin receptors 
(de Gasparo et al., 2000; Dzau & Gibbons., 1987; Ferrario et al., 1991; Griffin et al., 
1991; Peach et al., 1977; Schiavone et al., 1990; Unger et al., 1988; Weber et al., 
1995a,b). 
 
Angiotensinogen 
 
Angiotensinogen is a glycosylated α-2 globulin; its molecular weight is between 54 to 
60 kDa dependent on species. It is mainly produced in liver and secreted constantly. 
However, angiotensinogen mRNA can be detected in several tissues; e.g., the brain, 
the heart, the kidney, the adrenals, the ovaries and the testes (Campbell & Habener, 
1986; Cassis et al., 1988; Gomez et al., 1988). The release of angiotensinogen from 
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the liver is stimulated by bilateral nephrectomy, glucocorticoids, estrogen, thyroid 
hormone and Ang II (Campbell & Habener, 1986). The level of circulating 
angiotensinogen can decrease under certain pathological conditions; e.g., liver 
disease (Ayers, 1967), adrenal insufficiency (Carretero & Gross, 1967) and high 
sodium intake (Pratt et al., 1989). 
 
Renin 
 
Renin belongs to the family of aspartyl proteases and its amino acid sequence 
shares structural homology with other members of the family (Blundell et al., 1983; 
Dhanaraj et al., 1992; Tang et al., 1978). Renin is most active at neutral pH and 
shows an extremely high substrate specificity for angiotensinogen. 
Renin is produced and stored in the juxtaglomerular cells of the kidney. Translation of 
the renin gene yields preprorenin which is further processed to prorenin and renin 
(Hsueh et al., 1981; Leckie & McGhee, 1980). Renin is also expressed in other 
tissues, for instance in the liver, the heart and the blood vessels (Swales & Samani, 
1989), the brain (Dzau et al., 1986; Unger et al., 1988), the adrenal cortex (Dzau et 
al., 1987), the ovary (Kim et al., 1987) and the uterus (Shaw et al., 1989). 
It has been found that low, rather than high, plasma renin activity is associated with 
increased organ damage in hypertension. In contrast, other studies have indicated 
that low urinary sodium excretion and elevated plasma renin levels are associated 
with a greater risk of myocardial infarction and increased mortality. 
The control of renal renin secretion is quite complex. One of the well established 
stimuli is the signal from renal afferent arteriolar baroreceptors. Various hormones, 
including Ang II, arginine vasopressin, prostaglandins and natriuretic peptides 
participate in the regulation of renin release (Hackenthal et al., 1990). Recent data 
indicates that nitric oxide (NO) and endothelin can also be involved in the control of 
renin secretion (Ollerstam et al., 2001). 
Renin has been cloned from human (Soubrier et al., 1983), rat (Burnham et al., 1987) 
and mouse (Rougeon et al., 1981). The renin gene has a high sequence homology 
with cathepsin D. Humans and rats possess only one gene for renin. In the mouse, 
two renin genes have been identified, the Ren-1 and the Ren-2 gene. The major 
difference on the protein level is the presence of glycolysation sites on renin-1 
protein. 
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Angiotensin converting enzyme  
 
ACE is a peptidase with 150 kDa molecular weight. It cleaves the dekapeptide Ang I 
to generate the active Ang II. ACE is mainly localized in the vascular endothelium 
(Gohlke et al., 1992;). However, the enzyme is widely expressed in other tissues. 
ACE can also be detected in the epithelial cells of the kidney, in the heart, in the 
adrenal cortex and medulla, in the brain and the reproductive organs (Chai et al., 
1987; Correa et al., 1985; Jackson et al., 1988; Paul et al., 1985; Rix et al., 1981; 
Skidgel & Erdos, 1987; Yamada et al., 1991). Besides forming Ang II, ACE breaks 
down bradykinin (BK) into inactive fragments, degrades enkephalins, substance P 
and angiotensin 1-7 (Ang 1-7) (Chappell et al., 1998; Ehlers & Riordan, 1989; Skidgel 
et al., 1987; Unger & Gohlke, 1990). Glucocorticoids and the therapy with ACE 
inhibitors enhance the expression and the activity of ACE (Mendelsohn et al., 1982; 
Unger et al., 1981). 
The conversion of Ang I into Ang II can be effectively blocked by ACE inhibitors. 
Although ACE inhibitors suppress the activity of the RAS, at least part of their effects 
can be ascribed to an enhancement of BK effects. The ability of ACE inhibitors to 
reduce blood pressure due to suppression of Ang II production is extensively used in 
the treatment of hypertension. 
 
Synthesis of ANG II, the effector peptide of the RAS 
 
The sequence of Ang II is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe in human, horse and pig. 
Ang II is synthesized by a cascade of enzymatic reactions (Skeggs et al., 1980). In 
the first step, angiotensiongen is cleaved by renin to form biologically inactive Ang I. 
Subsequently, ACE converts Ang I into the active octapeptide Ang II by removing of 
two amino acid residues from the precursor. In this cascade, the formation of Ang I 
represents the rate-limiting step in the Ang II-synthesis and the major factor, which 
the activity of RAS depends on. 
Ang II is further metabolized to its derivatives. Aminopeptidase A subtracts one 
amino acid from Ang II to form angiotensin 2-8 (Ang III). Aminopeptidase N splices 
one amino acid from Ang III to form angiotensin 3-8 (Ang IV) which could be further 
degraded by a number of enzymes resulting in the formation of small amino acid 
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fragments. Some of the Ang II-derived metabolites possess biological activity 
(Ardaillou, 1997; Goodfriend, 1991; Qadri et al., 1998). 
 
Pharmacological characterization of angiotensin receptors 
 
Ang II exerts its actions initially by binding to its receptors. Since the discovery of the 
non-peptidergic, selective angiotensin receptor antagonists, losartan and PD123319, 
it has become clear that there are at least two different subtypes of angiotensin 
receptors, the AT1 and the AT2 receptor (Blankley et al., 1991; Duncia et al., 1990). 
Both receptors fulfill the criteria, which have been establish to identify and 
characterize distinct receptors. Two other angiotensin receptors (AT3 and AT4) have 
been proposed, based on operational criteria, but their transduction mechanisms are 
unknown and they have not yet been cloned.  
The AT1 receptor is a seven transmembrane domain receptor and belongs to the G 
protein-coupled receptor (GPCR) superfamily. Its affinity for Ang II is reduced in the 
presence of the reducing agent dithiothreitol (DTT) or GTP analogs. The AT1 
receptor mediates virtually all of the known physiological actions of Ang II in the 
peripheral tissue and the brain (de Gasparo et al., 2000). Vascular smooth muscle 
cells (VSMC) express almost exclusively AT1 receptors which are responsible for 
Ang II-induced vasoconstriction. Consequently, the selective AT1 receptor 
antagonists, the so called "sartan" compounds, are successfully used for treatment of 
hypertension (Unger, 1999).  
PD123319 and PD123177 are selective AT2 receptor antagonists since they bind 
with high affinity to the AT2 receptor. Another pseudopeptidergic compound, 
CGP42112, is a partial antagonist, since it can also displays agonistic effects, at 
higher concentrations. Like the AT1 receptor, the AT2 receptor also belongs to the 
family of seven transmembrane domain receptors. The binding of Ang II to the AT2 
receptor is not altered by DTT or GTP. The signaling mechanisms of the AT2 
receptor are less clearly defined than those of the AT1 receptor. 
Until now, the AT4 receptor has eluded molecular characterization. However, recent 
studies have identified the AT4 receptor to be insulin-regulated aminopeptidase 
which facilitates memory retention and retrieval in animals after binding with Ang IV 
(Albiston et al., 2001). 
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The AT1 receptor gene 
 
The AT1 receptor was successfully cloned in 1991. The human AT1 receptor gene is 
localized on the chromosome 3 (Curnow et al., 1992; Davies et al., 1994). The AT1 
receptor contains 359 amino acids. The amino acid sequence of the human AT1 
receptor is 95% identical with those of the rat and bovine AT1 receptors (Bergsma et 
al., 1992; Furuta et al., 1992). The open reading frame is located on exon 5 (Curnow 
et al., 1995). 
The AT1a and AT1b subtypes found in rats are highly homologous, 95% with respect 
to the amino acid sequence and 92% to nucleic acids (de Gasparo et al., 2000). The 
AT1a gene is composed of four exons, the third of which includes the entire 1077-
base pair (bp) coding sequence of the receptor protein as well as 5’ and 3’ un-
translated sequences. The gene is mapped on the chromosome 17 (Langford et al., 
1992; Murasawa et al., 1993) The rat AT1b receptor gene contains three exons. The 
open reading frame of the AT1b gene is located entirely in the third exon and the 
receptor is localized on the chromosome 2 (Tissir et al., 1995). Both AT1 receptor 
subtypes in the rat have similar pharmacological properties, but their distribution in 
tissues differ considerably.  
 
AT1 receptor expression and regulation 
 
The AT1 receptor is present in all tissues where Ang II is known to exert its classical 
effects. In human, AT1 receptors can be found in various tissues. The AT1 receptor 
is highly expressed in VSMC, the kidney, the uterus, the heart, the lung, the brain, 
and in the urinary tract (Ahmed et al., 1995; Allen et al., 1999; Mifune et al., 2001; 
Miyazaki & Ichikawa, 2001; Paradis et al., 2000; Vinson et al., 1995). In adult 
rodents, AT1a receptors are expressed in all of these tissues. AT1b receptors have 
been mainly identified in the adrenal and pituitary glands, some brain regions and the 
testis. VSMC contain only the AT1a receptor subtype (Burson et al., 1994; Gasc et 
al., 1994; Timmermans et al., 1992; Vinson et al., 1995). 
The presence and numbers of AT1 receptors vary considerably among different 
tissues. The patterns of the AT1 receptor distribution suggests that this angiotensin 
receptor subtype exerts very important biological activities in these tissues. The 
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expression of the AT1 receptor can be affected upon different pathological 
conditions, for instance in renovascular hypertension, after myocardial infarction, or 
bilateral nephrectomy, during the process of heart remodeling (Iwai & Inagami, 1992; 
Llorens-Cortes et al., 1994; Nio et al., 1995; Yamamoto et al., 2000; Zhu et al., 
2000). 
Treatment with glucocorticoids dramatically increases the expression of both types of 
AT1 receptors in the rat heart (Della Bruna et al., 1995). Estrogen treatment of rats 
was demonstrated to suppress the expression of AT1b mRNA level in the pituitary 
gland and to elevate the AT1a mRNA levels in smooth muscle cells (SMC) (Kakar et 
al., 1992; Nickenig et al., 1996). Other forms of a hormonal regulation of the AT1 
receptor expression have been reported, such as the insulin-induced up-regulation of 
AT1 receptors in VSMC. Progesterone, on the other hand, down-regulates the 
number of AT1 receptors in VSMC (Nickenig et al., 1998; Nickenig et al., 2000;). NO 
decreases, whereas epidermal growth factor (EGF) enhances the AT1a receptor 
gene expression in VSMC (Guo & Inagami, 1994, Ichiki et al., 1998). Ang II itself is 
able to down-regulate AT1 receptors in different cell types, such as in VSMC, 
mesangial cells and adrenal fasciculate reticularis cells (Ichiki et al., 2001; Makita et 
al., 1992; Naville et al., 1993).  
 
AT1 receptor signaling pathways  
 
The AT1 receptor signaling mechanisms have been intensively studied and the 
signaling pathways of the AT1 receptors are now largely well understood (de 
Gasparo et al., 2000). As a member of GPCR family, the AT1 receptor seems to 
couple mainly to Gq initiating the activation of phospholipase C (PLC) leading to 
phosphatidylinositol hydrolysis to form inositol triphophate (IP3) and diacylglycerol 
(DAG). IP3 evokes a subsequent increase in intracellular calcium, which mediates 
several of the effects regulated by the AT1 receptors, such as vascular smooth 
contraction, secretion of aldosterone from the adrenal cortex cells (de Gasparo et al., 
2000). 
Other G proteins, reported to mediate the AT1 receptor-induced effects, are the 
G12/13 family (leading to L-channel activation) and Gi/0 proteins (which inhibit adenylyl 
cyclase). In addition to these pathways, the binding of Ang II to its AT1 receptor also 
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leads to the phosphorylation of a number of downstream mediators like PLCγ or 
pp60c-src (de Gasparo et al., 2000).  
Recently, protein kinase C (PKC) beta subtype, which is stimulated by DAG, has 
been added to the array of AT1 receptor induced signaling. Most of these signaling 
cascades can finally result in the activation of inducible transcription factors such as 
c-Fos, c-Jun or KROX belonging to the DNA-binding proteins that regulate the 
expression of genes at the transcriptional level and thus transform the AT1 receptor-
mediated signal into cellular function (Blume et al., 1999). 
In addition, the AT1 receptor may play a role in the activation of mitogen-activated 
protein kinases (MAP kinases) as has been demonstrated in cardiac myocytes 
(Yamazaki et al., 1999). MAP kinases are serine/threonin protein kinases which are 
activated in response to growth factors and likely involved in the cell development 
and differentiation. After their stimulation, they translocate into the nucleus of the 
cells to stimulate nuclear transcription factors involved in the proliferation, 
differentiation, apoptosis (Ahn et al., 1990; Bucher et al., 2001).  
AT1 receptor can activate the JAK-STAT pathway and Jun-Kinase, other members of 
the MAP kinase family, to transduce cell surface signals into the cell cytoplasm and 
nucleus where they bind to specific DNA elements resulting in the transcription of 
early growth response genes, such as c-fos which lead to cell proliferation similar to 
cytokine receptors (Bhat et al., 1994; Blume et al., 1999; Leaman et al., 1996; 
Marrero et al., 1995). These findings provide very strong support for the role of the 
AT1 receptor in cellular growth through cross-talk with more than one tyrosine kinase 
systems. 
 
The AT2 receptor gene 
 
The AT2 receptor has been cloned from mouse, rat and human (Ichiki et al., 1994; 
Koike et al., 1995; Martin et al., 1994; Nakajima et al., 1993; Tsuzuki et al., 1994). In 
all three species, the AT2 receptor cDNA encodes for a 363 amino acid receptor. The 
sequence comparisons reveal a high homology on the nucleic acid as well as the 
amino acid levels (89% and 91%, respectively). The genomic DNA of all three 
species consists of three exons and its entire coding sequences are located in the 
third exon. The AT2 receptor genes in human, rats and  mice reside as a single copy 
on the X-chromosome (Koike et al., 1994). Comparisons of the AT1 and AT2 nucleic 
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acid sequences reveal only a poor, 34% homology. A complete divergence between 
AT1 and AT2 receptors is seen in the third intracellular loop, even more extensive 
differences have been found in the carboxyl terminal tail. 
The AT2 receptor protein contains 5 potential glycosylation sites in its extra-cellular 
N-terminal tail. In addition, there is a potential PKC phosphorylation site in the 
second intracellular loop. Furthermore, there are 3 consensus sequences for 
phosphorylation by PKC and one phosphorylation site by cyclic adenosine 3‘,5‘ 
monophosphate (cAMP)-dependent protein kinase in the c-terminal tail of the 
receptor in the cytoplasm (de Gasparo et al., 2000). 
 
AT2 receptor expression and regulation 
 
Compared to AT1 receptors, AT2 receptors are differently distributed in tissues. The 
AT2 receptor is predominantly expressed in fetal tissues. After birth, the ratio of AT1 
and AT2 receptor expression is reversed with the AT1 receptor subtype being the 
dominant one in most of the tissues of the adult organism (Unger, 1999). In the adult 
organism, both subtypes of angiotensin receptors can be found in the adrenal gland 
and vascular endothelial cells, the kidney and the heart, whereas the AT2 receptor 
predominates in the uterus, ovarian granulosa cells and some brain areas 
(Obermüller et al., 1991; Stoll et al., 1995; Unger, 1999). In the myometrium, the AT2 
receptor is predominantly expressed under non-pregnant conditions, the number of 
AT2 receptors declines during pregnancy, but returns to the non-pregnant level after 
parturition (de Gasparo et al., 1994).  
Although the AT2 receptor is not a common angiotensin receptor in a number of 
tissues in adult organisms, its expression can be dramatically increased under 
pathological conditions such as vascular injury, myocardial infarction, congestive 
heart failure, renal failure, brain ischemia, nerve transsection (Unger, 1999). 
An up-regulation of the AT2 receptor expression has been also observed after 
treatment with interlukin-1ß (IL-1ß), insulin, insulin-like growth factors (IGF), sex 
hormones. glucocorticoids, norepinephrine and growth factors down-regulate the AT2 
receptor expression (Mancina et al., 1996; Matsubara & Inada, 1998; Stoll et al., 
2002; Unger, 1999). Thus, it appears that a number of factors, particularly growth 
factors and hormones, can influence the expression of the AT2 receptor in various 
tissues (Stoll & Unger, 2001). 
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AT2 receptor signaling pathways 
 
The elucidation of the AT2 receptor-coupled intracellular signaling pathways turns out 
to be much complicated than in the case of the AT1 receptor. Although the AT2 
receptor has structural features commonly shared by seven transmembrane 
receptors, it does not reveal all functional features commonly attributed to this class 
of receptors. As stated below, the intracellular signaling pathways described for the 
AT2 receptor so far depend mostly on the type of the cell/tissue examined and 
employed experimental conditions.  
In contrast to the AT1 receptor, many studies on the signaling of the AT2 receptor 
have been performed in cells of neuronal origin (PC12W and NG 108-15 cell lines). 
Some features of the AT2 receptor make it unique among GPCR (Nouet & Nahmias, 
2000). Gi proteins seem to be the G protein subtype which may couple to the AT2 
receptor. A variety of signaling mediators have been characterized, with partly 
contradictory results. Thus, the AT2 receptor has been shown to mediate an increase 
as well as a decrease of intracellular cyclic guanosine 3’, 5’-monophosphate (cGMP), 
an activation or deactivation of early response kinase 1/2 (ERK 1/2) MAP kinases 
and an up- or down-regulation of phosphatases PP2A, MKP-1, SHP-1. The nature of 
the signal transduction pathways for this receptor is obviously to a high degree 
dependent on the total signal input into the cell at the time of the AT2 receptor 
stimulation. Thus, stimulation with Ang II leads to an early AT2 receptor mediated 
increase in ERK1/2 activity in PC12W cells; in contrast, a nerve growth factor (NGF)-
stimulated ERK1/2 activation in the same cells is later inhibited by AT2 receptor 
activation (Stroth et al., 2000). Other signal transduction molecules stimulated by 
AT2 receptor activation are particulate guanylate cyclase, T-type Ca2+ and K+ 
currents, NO release and activation of phospholipase A2, the latter resulting in the 
release of arachidonic acid and its metabolites and ultimately in the activation of the 
Ras kinase/MAP kinase pathway (de Gasparo et al., 2000). More recently, in vivo 
studies have shown that the AT2 receptor-induced release of arachidonic acid may 
contribute to the activation of Na+/HCO3- symporter system, which regulates 
intracellular pH. Thus, the AT2 receptor seems also to be involved in the processes 
regulating intracellular pH following injury (Haithcock et al., 1999; Kohout & Rogers., 
1995). As already mentioned above, activation of guanylate cyclase by the AT2 
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receptor increases cellular cGMP levels, NO production and its release (Gohlke et 
al., 1998; Liu et al., 1997; Siragy & Carey, 1996; Wiemer et al., 1993).  
It has been demonstrated recently, that Ang II acting on the AT2 receptor can induce 
apoptosis. The apoptosis-promoting properties of the AT2 receptor have been shown 
to involve ceramide generation as well as activation of caspase 3 (Dimmeler et al., 
1997; Gallinat et al., 1999; Lehtonen et al., 1999) (see below).  
The effect of Ang II on cell proliferation/apoptosis and differentiation may be, at least 
partly, attributed to the AT2 receptor-induced stimulation on MAP kinase activity 
(Horiuchi et al., 1998; Lehtonen et al., 1999; Stroth et al., 2000). Recent studies in 
VSMC indicate that the AT2 receptor activates not only the ERK MAP kinases but 
also Janus kinases and signal transducers and activators of transcription (Jak/STAT) 
which seem to be the key elements of signaling pathways for growth factors and 
cytokines to stimulate the growth of these cells (Stoll & Unger, 2001).  
Recently, our group has identified a zincfinger homoeodomain enhancer binding 
protein gene (Zfhep) encoding for a transcription factor, which is expressed after 
activation of the AT2 receptor in cells of neuronal and vascular origin. Zfhep may 
represent a link between the AT2 signaling and downstream events involved in 
proposed effects of the AT2 receptor in the development and regeneration (Stoll et 
al., 2002). 
 
Local renin angiotensin systems (RASs) 
 
In addition to the systemic RAS, the existence of tissue RASs has been established. 
The tissue RASs express all key RAS components, notably angiotensinogen and 
renin, independently of the circulating RAS. The existence of local RAS has been 
demonstrated in various tissues and cell lines such as in the pancreas, the brain, the 
adrenal gland, the heart blood vessels, the uteroplacental unit, the human uterine 
decidual cells (Bader et al., 2001; Leung & Carlsson, 2001; Li et al., 2000; Nielsen et 
al., 2000; Sigmund, 2001). Tissue RASs have been implicated; e.g., in the local 
regulation of blood flow, angiogenesis, proliferation and differentiation of cells, 
inflammation and tissue remodeling independently of systemic RAS. For instance, 
the RAS in the brain participates in the regulation of blood pressure, drinking 
behavior, natriuresis, secretion of pituitary hormones (Culman et al., 2001). A local 
RAS in adipose tissue has also been identified. Interestingly, this RAS has been 
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implicated in the pathogenesis of hypertension and some obesity-related disorders in 
humans (Engeli et al., 1999). 
A number of experiments have been carried out to characterize the Ang II receptors 
in the uterus and to study the regulation of their expression in different species. The 
human non-pregnant uterus expresses the AT2 receptor at a high proportion as 
compared to the AT1 receptor. Similarly, in the myometrium of porcine uterus, the 
AT2 receptor is highly expressed; its expression is, however, down-regulated during 
gestation. Species dependence exits, as only 40% and 60% of Ang II-binding sites 
are AT2 receptors in the rat and rabbit uterus, respectively (de Gasparo et al., 2000). 
In contrast, the AT1 receptor is expressed in the myometrium independently of the 
gestation (Nielsen et al., 1997). The expression of the AT2 receptor in the human 
myometrium varies dramatically during the menstrual cycle (Mancina et al., 1996). 
 
Regulatory functions of the RAS 
 
RAS and cardiovascular system 
 
Ang II regulates blood pressure through peripheral and central mechanisms. In the 
periphery, Ang II directly induces vasoconstriction by activating of AT1 receptors 
located on VSMC and causes sodium retention in the kidney through stimulation of 
aldosterone release from the zona glomerulosa in the adrenal gland and by a direct 
tubular mechanism. Ang II via the AT1 receptor facilitates peripheral noradrenergic 
neurotransmission by augmenting norepinephrine release from sympathetic nerve 
terminals and by enhancing the vascular response to norepinephrine (Balt et al., 
2001). Ang II also facilitates vasoconstriction by stimulation of the catecholamine 
release from the adrenal gland (Peach et al., 1966). This effect can be attributed to 
Ang II circulating in blood as well as to the peptide synthesized locally in the adrenal 
tissue. Enhanced expression of endothelin-1 in response to Ang II may further 
contribute to the vasoconstrictor effects of Ang II (Hahn et al., 1993). While the AT1 
receptor induces vasoconstriction and increases the blood pressure, the AT2 
receptor exerts opposite effects. AT2-null mice show a slight elevated blood pressure 
which further increases during Ang II infusion (Siragy & Carey, 1999). 
In addition to the peripheral effects, Ang II in the brain regulates blood pressure 
through the release of vasopressin modulation of the sympathetic activity and the 
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attenuation of the baroreceptor reflex. These effects are mediated by central AT1 
receptors (Höhle et al., 1995). Additionally to these effects, Ang II acting on 
periventricular and hypothalamic areas induces an immediate drinking response. The 
peptide is also involved in the regulation of the release of a number of hormones 
from the pituitary gland into the circulation (Saavedra, 1992). 
In the periphery, Ang II can induce heart- and vascular hypertrophy independently on 
its pressor mechanisms. Treatment of spontaneously hypertensive rats (SHR) with 
sub-antihypertensive doses of ACE inhibitors results in a decrease in cardiac 
hypertrophy (Baker et al., 1990). Studies in our laboratory have also demonstrated a 
regression of the left ventricular mass in SHR treated with sub-antihypertensive 
doses of ramipril, an ACE inhibitor (Gohlke et al., 1996; Gohlke et al., 1994). These 
findings clearly indicate that Ang II directly promotes cardiac growth independently of 
its haemodynamic effects.  
The AT2 receptor has been implicated in events associated with cardiac remodeling 
after myocardial infarction. Increased expression of this angiotensin receptor 
subtypes has been observed after myocardial infarction or in failing heart (Matsumoto 
et al., 2000; Tsutsumi et al., 1998; Zhu et al., 2000). 
  
RAS and growth, proliferation and differentiation  
 
High expression of the AT2 receptor during embryogenesis indicates that Ang II may 
participate in the regulation of both, cell proliferation and differentiation. The low 
expression of the AT2 receptor in early embryonic stages but its very high levels 
during late embryonic development and rapid decline in the neonatal period suggest 
a role for the AT2 receptor in fetal vascular development in late embryonic and early 
postpartum development (Shanmugam et al., 1995; Viswanathan et al., 1991). 
Evidence for an antiproliferative effect of Ang II through the activation of its AT2 
receptors first came from the study in coronary endothelial cells (CEC) (Stoll et al., 
1995) and have been confirmed later, in NG108-15 cells, PC12W cells, R3T3 cells, 
renal mesangial cells (Goto et al., 1997; Laflamme et al., 1996; Meffert et al., 1996; 
Munzenmaier & Greene, 1996; Tsuzuki et al., 1996).  
In VSMC, which express only AT1 receptors in culture, Ang II exerts a growth-
promoting effect. However, in cells transfected with the AT2 receptor, the proliferation 
is reduced and MAP kinase activity is inhibited. Similarly, in NIE-115 cell line, the AT2 
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receptor inhibits the activity of MAP kinases and suppressed thus the cell growth 
(Bedecs et al., 1997). Similar effects have been observed in fibroblasts, PC12W cells 
and neuronal cells (Huang et al., 1996; Meffert et al., 1996; Yamada et al., 1996). 
In vivo experiments employing transfection of an AT2 receptor expression vector into 
the balloon-injured rat carotid artery demonstrate that the over-expression of the AT2 
receptor attenuates the neointima formation (Nakajima et al., 1995). This finding 
indicates that the RAS has the possibility to balance via activation of AT2 receptors 
the growth response elicited by Ang II through the AT1 receptor. 
The stimulation of PC12W cells, which express exclusively the AT2 receptor, 
stimulation with NGF is extensively used as a model to study neuronal differentiation. 
Treatment of PC12W cells with NGF up-regulates protein filaments, like 
microtubules, actin filaments and intermediate filaments which play a crucial role in 
the stability and function of neuronal PC12W cells. AT2 receptor activation by daily 
treatment of the PC12W cells with Ang II not only directly promotes neuronal 
differentiation, as evidenced by augmented neurite outgrowth and by up-regulation of 
polymerised tubulin, but also significantly enhances the NGF-mediated morphological 
differentiation (Meffert et al., 1996). Comparison of the effects of NGF on tubular and 
neuroskeleton proteins with those of the AT2 receptor reveals similarities; e.g., the 
up-regulation of β-tubulin, but also conspicuous differences. Whereas NGF up-
regulates neurofilament M (NF-M), a cell differentiation marker, the AT2 receptor not 
only down- regulates this protein but also inhibits the NGF-induced up-regulation of 
this neurofilament in PC12W cells (Gallinat et al., 1997). These results suggest that 
the NGF-induced mechanisms leading to differentiation in PC12W cells are distinct 
from those induced by Ang II via the AT2 receptor. Similar effects have been 
observed in the neuronal cell line NG108-15 (Laflamme et al., 1996). 
 
RAS and tissue regeneration 
 
In general, the process of wound healing and tissue repair is controlled by a variety 
of mechanisms. Recent findings indicate that Ang II may interfere with these 
processes as increased tissue levels of the AT2 receptor have been observed after 
skin injury or after myocardial infarction (Unger, 1999). Since it has become apparent 
that Ang II acting through the AT2 receptor plays a role in wound healing and repair 
of peripheral tissues, the attention of investigators has turned to the role of Ang II in 
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processes occurring during regeneration after injury of neuronal tissue. Adult neurons 
usually do not re-innervate their target regions after injury, probably due to absence 
of requisite neurotrophic agents. However, if they are supplied with growth-promoting 
substances, they are able to generate new processes over long distances and, 
eventually, re-innervate their target region. Stimulation of AT2 receptors in PC12W 
cells down-regulates NF-M as it occurs in nerve fibre regeneration (Gallinat et al., 
1997). Reduced neuronal expression of this protein has been found following nerve 
transection (Lucius et al., 1998). Following sciatic nerve transection, a several-fold 
up-regulation of mRNA coding for the AT1 and AT2 receptors is demonstrated in 
dorsal root ganglion neurons and in sciatic nerve segments proximal and distal to the 
cell body. Sciatic nerve crush results in a time-dependent up-regulation of AT2 
receptor mRNA levels in sciatic nerve segments which coincides with the successful 
regeneration of nerve fibres (Gallinat et al., 1998). These findings indicate that the 
AT2 and AT1 receptor-mediated pathways are involved in Schwann cell-mediated 
myelination and in the control of neuroregenerative responses in the peripheral 
nervous system.  
Ang II-mediated effects have also been investigated in axonal regeneration of 
postnatal rat retinal explants and cultured dorsal root ganglion cells (DRGCs). In the 
in vitro model of postnatal retinal explants and cultured DRGCs, which are 
comparable with adult, non-regenerating DRGCs, as well as in the in vivo model of 
optic nerve crush, Ang II induces a concentration-dependent outgrowth of neurites. 
These effects of Ang II, both in vitro and in vivo, are mediated by the AT2 receptor. 
Like in the previous studies carried out on peripheral nerves, the regeneration 
process is paralleled by a time-dependent increase in AT2 receptor mRNA 
expression in the retina and the crushed optic nerve (Lucius et al., 1998). These 
findings point to a role of Ang II and its receptors in the regeneration processes 
occurring in neuronal tissue following injury and provide a direct evidence that 
stimulation of AT2 receptors promotes axonal regeneration not only in vitro, but also 
under in vivo conditions after neuronal lesion.  
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RAS and apoptosis 
 
Apoptosis, is a prominent feature of normally developing tissues, as well as tissues 
that have undergone injury or damage. The intricate balance between pro- and anti-
apoptotic proteins determines whether the cell will undergo apoptosis or survive. 
Several studies have reported that increased AT2 receptor expression in a 
developing fetus correlates with extensive apoptosis (Chamoux et al., 1999).  
Neurons undergo apoptosis after ischemiac insult or when they are seriously injured; 
e.g., after axotomy. The risk of apoptosis and the potency for axonal degeneration 
are closely related: lesions occurring close to the neuronal cell bodies initiate a 
potent cell body response directed towards regeneration, but simultaneously, the risk 
of apoptosis is high. Neuron lesion more distally usually do not undergo apoptosis 
but the regeneration processes are weak. These observations suggest that neuronal 
injury or damage initiates a series of molecular events which are identical for both, 
regeneration and apoptosis. Generally, the classical MAP kinase cascades, like the 
ERK1/2 pathway, the stress-activated protein kinase (SAPK) cascade (JNK pathway) 
and the p38 pathway have been implicated in apoptosis. ERK1 and ERK2 kinases 
inhibit apoptosis whereas SAPK and p38 act pro-apoptotic. It is likely that a dynamic 
balance between the SAPK cascades and MAP kinases plays a critical role in cell 
survival and death (Kinloch et al., 1999). 
Recent findings indicate that Ang II acting on its receptors not only exerts growth 
promoting effects or promotes neuronal differentiation and regeneration, but is 
involved in the regulation of cellular pro- and anti-apoptotic events. It has been 
demonstrated that the AT2 receptor exerts growth inhibitory and pro-apoptotic effects 
by antagonising the effects mediated by the AT1 receptor or growth factors in various 
cell lines, like VSMC, neuronal PC12W cells or fibroblasts. Stimulation of the AT2 
receptors in serum-deprived PC12W cells is reported to induce apoptosis (Yamada et 
al., 1996). In these cells, NGF inhibits the internucleosomal DNA fragmentation 
induced by serum deprivation, whereas Ang II upon binding to AT2 receptors 
antagonises the NGF-mediated survival and induced apoptosis. The pro-apoptotic 
events mediated by the AT2 receptor include activation of tyrosin phosphatases such 
as MKP-1 and inactivation of MAP kinase (ERK1/2) which results in Bcl-2 protein 
dephosphorylation (inactivation of an anti-apoptotic factor) and up-regulation of the 
pro-apoptotic Bax protein (Horiuchi et al., 1998; Horiuchi et al., 1997). Analysis of 
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functional domains of the AT2 receptor in neuronal PC12W cells has revealed that 
the intermediate portion of the intracellular third loop is important for the apoptotic 
effects mediated by this receptor (Lehtonen et al., 1999). The axotomy-induced AT2 
receptor up-regulation associated with the down-regulation of neurofilament M (NF-
M) can also be interpreted in terms of apoptosis rather than neuronal regeneration 
(Gallinat et al., 1997). Ceramides, which are generated by a PLC type reaction from 
the precursor sphingomyelin, serve as mediators of the cellular responses to a 
variety of apoptotic stimuli. The molecular mechanisms responsible for the ceramide-
induced cell death involve in activation of stress kinases or caspases (Hofmann & 
Dixit, 1998). We have recently demonstrated that stimulation of the AT2 receptors 
selectively induces de novo synthesis of ceramides in PC12W cells (Gallinat et al., 
1999). The AT2 receptor-induced ceramide accumulation precedes the onset of 
caspase 3 activation and DNA fragmentation (Lehtonen et al., 1999). An interesting 
new aspect of AT2 receptor signaling has been shown recently in several cell types: 
the ligand-independent signaling of the AT2 receptor. An over-expression of the 
receptor without binding of Ang II is sufficient to induce apoptosis (Miura & Karnik, 
2000). 
 
Links between the kallikrein-kinin system and the RAS system 
 
The plasma kallikrein-kinin system (KKS) has been traditionally linked to physiologic 
hemostasis. In the recent years, the link between the BK and NO production and NO-
mediated effects has increasingly attracted the attention of scientists (Tschope et al., 
2002). The endothelial cell- associated active kallikrein cleaves the high-molecular 
weight kininogen to form BK, which can then activate its B2 receptor. Activation of 
this receptor regulates vascular tone by stimulating NO formation in endothelial cells 
(Schmaier, 2002). The B2 receptor knock-out mice is a very useful model to study 
the physiological relevance of the KKS and the interaction between this system and 
the RAS. These mice develop mild hypertension, cardiac hypertrophy, chamber 
dilatation and myocardial damage, elevated left ventricular and end-diastolic 
pressure, and they show exaggerated vasopressor response to Ang II. In the 
presence of Ang II, these mice have increased blood pressure and reduced renal 
blood flow (Emanueli et al., 1999; Madeddu et al., 1999). ACE and 
prolylcarboxypeptidase (PRCP) are the key molecules which interfere with both 
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systems. As already mentioned, ACE converts inactive Ang I to the vasoconstrictor 
peptide Ang II. The same enzyme also degrades BK to BK(1-7) and BK(1-5). PRCP is 
the enzyme which degrades Ang II to the vasodilating peptide Ang (1-7). This peptide 
also stimulates NO and prostaglandin (PGI2) formation which potentate the effects of 
BK. PRCP has also the ability to convert prekallikrein to kallikrein, which cleaves 
kininogen to liberate BK. Thus, PRCP is the enzyme which degrades the 
vasoconstrictor peptide Ang II and forms the vasodilator BK and Ang (1-7). BK 
stimulates NO and prostaglandin PGI2 formation, thus counterbalancing the 
vasoconstrictor effects of Ang II (Fig 1) (Schmaier, 2002). 
ACE inhibitors have been successfully introduced in the treatment of hypertension 
and other cardiovascular diseases. The improvement of cardiac, renal and 
endothelial functions observed after treatment with ACE inhibitors appears to be, at 
least partly, B2 receptor-mediated, as evidenced by an increased NO production and 
their reversal by B2 receptor antagonism (Cachofeiro et al., 1995; Linz et al., 1995). 
AT1 receptor antagonists have been shown to produce similar effect like ACE 
inhibitors with respect to the improvement of cardiac, vascular and renal functions. 
The underlying mechanism seems to involve the AT2 receptor. When AT1 receptors 
are blocked, Ang II can increasingly interact with AT2 receptors, as AT1 receptor 
antagonists leave the AT2 receptor unopposed and rather expose it to elevated Ang 
II levels (Carey et al., 2001; Sosa-Canache et al., 2000). There is only indirect 
evidence pointing to a link between the AT2 receptor and the BK-system. 
Experiments employing bovine endothelial cells, rat carotid arteries, canine coronary 
arteries or rat kidney have demonstrated that Ang II can stimulate NO production, 
and this effect is, at least partly, mediated by BK (Boulanger et al., 1995; Seyedi et 
al., 1995; Wiemer et al., 1993). These findings indicate that Ang II acting on the AT2 
receptor can enhance the production of BK and NO and thus indirectly interfere with 
the regulation of BK-mediated responses (Siragy et al., 1999). Moreover, activation 
of AT1 receptors triggers the formation of reactive oxidant species which play a role 
in the pathophysiology and progression of cardiovascular diseases (Ichiki et al., 
2001). Stimulation of AT2 receptors has opposite effects since augmented NO 
generation due to increased BK production neutralises superoxide anions (Tsutsumi 
et al., 1999). 
Several recent studies have also suggested a link between the BK/NO system and 
organ protection. As already stated, BK through its B2 receptor triggers a cascade of 
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events, comprising liberation of PGI2 and NO and stimulation of soluble guanylate 
cyclase to form cGMP (Higashida et al., 1999). Recent data from our group indicate 
that Ang II via its AT2 receptor increases aortic cGMP levels in the aorta of SHR, in 
bovine aortic endothelial cells and in PC12W cells. Both, the activation of NO 
synthase and the stimulation of the B2 receptor, are involved in the AT2 receptor-
mediated Ang II effect on cGMP levels (Gohlke et al., 1998).  
 
PC12W, CEC and SK-UT-1 cells: models to study the functions of the AT2 
receptor  
 
AT2 receptors are highly expressed in a number of cell lines, like pheochromocytoma 
cell line (PC12W cells), Swiss mouse 3T3 fibroblasts (R3T3 cells) and mouse 
neuroblastoma cell line (NG108-15). In general, these cells express exclusively AT2 
receptors, but not AT1 receptors up to certain cell passages, and are, therefore, very 
useful to study the regulation, signal transduction pathways, function and 
(patho)physiological relevance of the AT2 receptor. 
Uterus leiomyosarcoma, a type of smooth muscle neoplasm of the uterus, is 
extremely malignant with high rates of local recurrence and metastasis to distant 
sites. SK-UT-1 is a human uterus leiomysarcoma cell line derived from a human 
mixed malignant mesodermal tumor of the uterus obtained from a single biopsy of 
the sarcoma. It belongs to myometrial cell lines. This cell line has a higher number of 
insulin-like growth factor (IGF) II receptors than insulin- and IGF I receptors. IGF-II is 
highly potent in stimulating the proliferation of these cells, IGF-I has, on the contrary, 
no effect. Insulin can stimulate the DNA synthesis only at higher, pharmacological 
concentrations (Nagamani & Stuart, 1996). TC21 is the fourth member of the ras 
gene family and the mutation of this gene is related to uncontrolled proliferation of 
these cells. A mutation comprising an insertion of nine base pairs at TC21 codon 24 
could be detected in SK-UT-1 cells (Huang et al., 1995). It has been found that all 
cAMP-dependent as well as some basal biglycan, a prototype member of the 
proteoglycan family, negative feedback loops regulating transforming growth factor 
(TGF)-ß, transcription in SK-UT-1 are mediated through activated protein kinase A 
(Ungefroren et al., 1998). 
Coronary endothelial cells, primary cells isolated from the rat coronary artery, are 
characterized by their cobblestone morphology and the presence of the receptors for 
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acetylated LDL (Voyta et al., 1984). The purity of the cell culture must be verified by 
staining with a monoclonal antibody for smooth muscle α-actin to exclude pericyte 
contamination. These cells have both Ang II receptor subtypes: the AT1 and AT2 
receptor (Stoll et al., 1995). 
The PC12W cell line is a sub-strain from a clonal isolation of a rat adrenal chromaffin 
cell tumor (Greene and Tischler, 1976). PC12W cells exclusively express AT2 
receptors at lower, less that 18, cell passages. Most of the studies on the signaling 
pathways of the AT2 receptor have been performed in these cells. Experimental 
results obtained from this cell line might be representative of the AT2 receptor 
functions in neuronal tissues. These tumor cells of neuronal origin are widely used to 
study neurotransmitter synthesis and release, ionic channels and mechanisms of 
actions of growth factors, like NGF.  
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Fig 1 The interaction between the plasma KKS and RAS. Plasma kallikrein 
converts prorenin to renin, and renin has the ability to convert angiotensinogen to 
Ang I. ACE converts inactive Ang I to the vasoconstrictor Ang II. Ang II stimulates 
plasminogen activator inhibitor 1 (PAI1) release from endothelial cells. At the same 
time ACE degrades BK into BK(1–7) (not shown) or BK(1–5), a peptide with thrombin 
inhibitory activity. PRCP is the enzyme that degrades Ang II or Ang I to the 
vasodilating peptide, Ang II(1–7). Ang II(1–7) stimulates NO and PGI2 formation, 
which potentiates the effects of BK. PRCP also has the ability to convert PK to 
kallikrein. Formed kallikrein digests kininogens to liberate BK, leaving a kinin-free 
kininogen (HKa) that has anti-proliferative and anti-angiogenic properties. Thus, 
PRCP, the same enzyme that degrades the vasoconstrictor Ang II, leads to the 
increased formation of the vasodilators BK Ang II(1–7). Finally, the resulting BK 
stimulates tPA, NO, and PGI2 formation, thus counterbalancing the prothrombotic 
effect of Ang II (Schmaier, 2002). 
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Questions Addressed 
 
Section I  
 
The AT2 receptor is abundantly expressed in the adult uterus, and its levels depend 
on the menstrual cycle. Physiologically, the AT2 receptor seems to be involved in the 
control of menstrual cycle and reproduction. The expression of the AT2 receptor in 
malignant tumor cells of human uterus leiomyosarcoma SK-UT-1 cells may indicate a 
role of Ang II in a number of events associated with proliferation, differentiation or 
apoptosis. 
 
First, it was intended to investigate whether the expression of the AT2 receptor in 
uterus tumor cells is regulated by growth factors. 
 
The AT2 receptor has been demonstrated to inhibit growth in CEC (Stoll et al., 1995) 
and PC12W cells (Meffert et al., 1996). The question arises, whether an activation of 
the AT2 receptor promotes or inhibits proliferation of SK-UT-1 cells. If Ang II inhibits 
growth of these cells, does the peptide promote their differentiation? Is there 
reciprocal relationship between the degree of differentiation and the level of 
proliferation in these cells? 
 
Ang II acting on the AT2 receptor can induce apoptosis in PC12W cells (Gallinat et 
al., 1999). Do the leiomyosarcoma cells also undergo apoptosis after their exposure 
to Ang II? Is these effect mediated by the AT2 receptor? 
 
Section II 
 
Former studies have demonstrated the presence of both angiotensin receptor 
subtypes in CEC. Generally, activation of the AT2 receptor induces growth inhibition. 
The AT2 receptor may exert its growth-modulatory- and differentiation-stimulatory 
actions on various levels including the modulation of the signaling of other receptors 
and the activity of growth- and transcription factors, as well as the remodeling of the 
extracellular matrix. Enhanced expression of Zfhep may represent one of the 
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mechanism by which the AT2 receptor promotes cell differentiation in various cells. In 
the second set of the experiments, It was investigated whether Ang II affects the 
gene expression of Zfhep in rat CEC. These cells express AT1 as well as AT2 
receptors. Assuming that the Zfhep expression is regulated by Ang II in CEC, it would 
be important to demonstrate, which angiotensin receptor subtype mediates this 
effect.  
 
Section III 
 
Several studies have demonstrated that Ang II can increase cGMP levels. The 
mechanism involves activation of the B2 receptor by BK and NO formation. We have 
demonstrated previously, that the AT2 receptor is involved, since inhibition of this 
angiotensin receptor subtype completely abolished the Ang II-induced cGMP 
formation (Gohlke et al., 1998). Activation of the AT2 receptor induces differentiation 
in PC12W cells (Meffert et al., 1996) and this effect may involve the BK/NO cascade.  
Following questions are to be answered: 
Does blockade of the B2 receptor or inhibition of NO synthases (NOS) attenuate the 
effect of Ang II on the differentiation of PC12W cells? Is the generation of cGMP a 
prerequisite of the differentiation in PC12W cells?  
Can sodium nitroprusside, an exogenous NO-donor, induce differentiation in PC12W 
cells independently of AT2 receptor stimulation? 
Providing that inhibition of NOS attenuates the Ang II-induced differentiation of 
PC12W cells, can an exogenous NO-donor reverse this effect? 
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Materials and Methods 
 
Equipments 
 
eukaryotic cell incubator: IG 150   Jouan, Unterhaching, Germany 
bacterial incubator     Jouan, Unterhaching, Germany 
bacterial incubator/Shaker: Innova 4000 New Brunswick Scientific, USA 
eppendorf incubator: Thermomixer 5436 Eppendorf, Hamburg, Germany 
water baths      GFL, Burgwedel, Germany 
spectrophotometer: U-2000   Hitachi ltd, Tokyo, Japan 
benchtop centrifuge MR1822   Jouan, Unterhaching, Germany 
centrifuge: Minifuge RF Heraeus sepatech, Hannover ermany 
electrophoresis apparatus: Horizon 11-14 Gibco BRL, Eggenstein, Germany 
video imaging documentation system  Intas, Germany 
hybridization oven     Biometra, Göttingen, Germany 
electrophoresis apparatus: Vertical 15-17 Gibco BRL, Eggenstein, Germany 
β-counter: Wallac 1409 liquid  
scintillation counter     Berthold GmbH,Wildbad,Germany 
γ-counter: Wallac 1470 Wizard   Berthold GmbH,Wildbad,Germany 
sonicator: Sonoplus GM70   Bandelin electronics, Berlin, Germany 
 
Angiotensin receptor ligands 
 
PD123177, PD123199, losartan were kindly gifts from respectively: 
Dr. David Taylor at Parke Davis Pharmaceutical Research Division, Warner-Lambert 
Company, Ann Arbor MI, USA. 
Dr. Marc de Gasparo at Novartis, Pharmaceutical Research Division, Basel, 
Switzerland. 
Dr. Ronald Smith at Dupont Merck Pharmaceutical Company, Wilmington DE, USA. 
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Angiotensin  II      Sigma, Deisenhofen, Germany  
 
Growth factors 
bFGF, human recombinant growth factor Hofmann La Roche Mannheim 
Biochemica, Mannheim, 
Germany 
NGF        Sigma, Deisenhofen, Germany 
 
Salts, acids, organic solutions: 
NaCl, MgCl2 EDTA, HCl, acetic acid, ethanol, etc Merck, Darmstadt, or Sigma 
Deisenhofen, Germany 
 
General cell culture conditions 
 
Cell lines: 
 
SK-UT-1 cells (ATCC HTB 114) were kindly provided by Dr. Hendrik Ungefroren, Kiel 
Germany.  
PC12W cells, were kindly provide by Dr. Serge Bottari, Grenoble, France. 
The coronary endothelial cells (CEC) were isolated by from male Wistar rats (Stoll et 
al., 1995). 
 
Reagents 
 
Dulbecco’s modified essential medium  GibcoBRL, Eggenstein, Germany 
(DMEM) without sodium pyruvate, with 4500 mg/l glucose 
Dulbecco’s modified. essential medium  Gibco BRL, Eggenstein, Germany 
(DMEM) with1000 mg/L Glucose, with sodium pyruvate, with pyridoxine 
without phenol color 
Nutrient mixture F-12 (HAM´-12)   Gibco BRL, Eggenstein, Germany 
Fetal calf serum (FCS)    Biowhittaker Bioproducts 
Walkersville MD, USA 
Horse serum (HS)     Bioconcept, Umkirch, Germany 
Trypsin (10 X )     Gibco BRL, Eggenstein, Germany 
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Trypsin/EDTA (10 X)    Gibco BRL, Eggenstein, Germany 
Penicillin:streptomysin 
(10,000 IU/ml:10,000 µg/ml)   Gibco BRL, Eggenstein, Germany 
PBS: 140 mM NaCl; 2,8 mM KCl; 8.1 mM Seromed, Berlin, Germany 
Na2HPO4; 1.5 mM KH2PO4; 0.5 mM MgCl2 pH (7.4) 
L-Glutamin (100 X )     Gibco BRL, Eggenstein, Germany 
 
Culture dishes: 
 
10 cm dishes or 6 well, 24 well plates and  
6 well plates      Nunc, Wiesbaden, Germany 
 
 
Protocols: 
 
SK-UT-1 cells were cultured under combination with DMEM (without phenol color) 
and Ham‘-12 as 1:1, supplemented 1% penicillin:streptomycin (100 IU/ml:100 µg/ml) 
and 10 % iFCS, 2 mM of L-Glutamin. The cell line was passed using 1.5 X 
trypsin/EDTA. 
PC12W cells were kept under DMEM (without sodium pyruvate) supplemented with 
10% iHS, 5% iFCS and 1% penicillin:streptomycin (100 IU/ml:100 µg/ml). This cell 
line was passed using 1 X passage/EDTA. PC12W cells were used from passage 14 
to 17. 
Coronary endothelial cells (CEC) were isolated from male Wistar rats and cultured in 
DMEM with 10% iFCS and 1% pencilline:streptomycin (100 IU/ml:100 µg/ml) and 
passed with 1 X trypsin/EDTA. 
All cells were usually grown as a monolayer in appropriate dishes at 37°C in a 
humidified atmosphere of air/CO2 (19:1). To achieve quiescent cells, SK-UT-1, 
PC12W cells and CEC were serum-deprived for 48 hrs prior to the experiments. 
 
Receptor radioligand binding assay  
 
Expression of receptors on whole cells can be detected with radio-labeled ligands. 
Competition for the binding site between the radioactive labeled Ang II and an excess 
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of the AT1 or the AT2 specific ligands allowed the detection of angiotensin receptor 
subtypes on the cell surface. 
 
Reagents: 
 
Ligands: see section “angiotensin receptor ligands“ 
[125I ] Tyr4-ANG II (agonist)    NEN life Science Products 
Specific activity of 2200 Ci/mmol    Boston MA, USA 
 
Protocol: 
 
Cells were grown as a monolayer in 24 well dishes (500 µl medium/well). [125I ] Tyr4-
ANG II (40 pmol/single well) was usually added to the medium (500 µl/well) for 2 hrs, 
at 37°C. The cells were washed twice with ice-cold PBS and solubilized in 1 N NaOH 
for 20 min at 37°C. The solubilized material was then counted for γ-radioactivity. Non-
specific binding was performed in parallel cultures, incubated with [125I ] Tyr4-ANG II 
in combination with 1 µM Ang II and was usually less than 2% of total binding. To 
determine the receptor binding specificity, cells were incubated with [125I ] Tyr4-ANG II 
in combination with specific angiotensin receptor antagonists (1 µM each). 
 
Thymidine incorporation assay 
 
Cells were cultured in the presence of [methyl,1,2-3H]-thymidine to measure the 
capability of Ang II to affect growth activity through the activation of the AT1 and/or 
AT2 receptor. The amount of labeled thymidine incorporated into the DNA of the cells 
is a parameter of cell growth activity.  
 
Reagents: 
 
[methyl,1,2-3H]-thymidine, specific activity:  NEN life Science Products 
90-120 Ci/mmol      Boston MA, USA 
Liquid scintillation cocktail: Ready Protein+  Beckman, Frankfurt, Germany 
Fixative solution: 10% trichloroacetic acid solution Merck, Darmstadt, Germany 
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Protocol: 
 
SK-UT-1 cells were plated in 24 well plates at concentration of 5 × 104/ml and left to 
grow for 24 hrs. Cells were serum deprived for 48 hrs prior to the thymidine assay. 
Then, Ang II alone or Ang II together with the AT1 or the AT2 antagonist was added 
with [methyl,1,2-3H]-thymidine (1 µCi/well) to the appropriate medium for 24 hrs. On 
the following day, the radioactive media were removed and the cells were washed 
with cold PBS (0.5 ml/well). The cells were fixed with 10% trichloroacetic acid 
solution (0.5 ml/well) overnight in an incubator at 37°C. Subsequently, the fixative 
solution was removed, followed by a wash with cold PBS. The cells were lysed in 
NaOH (0.1 N 400 µl/well) for 1 hr at room temperature by shaking at 250 rpm/min. 
Finally, 200 µl of the lysate were transferred to scintillation vials containing 4 ml of 
liquid scintillation cocktail solution. The radioactivity was counted in a β-counter for 5 
min. 
 
Cell counting procedure  
 
To measure the growth activity, cells were counted using a hemocytometer under a 
conventional light microscope. 
 
Reagents: 
 
Trypan blue dye     Sigma, Deisenhofen, Germany 
Trypsin/EDTA (10X)    Gibco BRL, Eggenstein, Germany 
Phosphate-buffered saline (PBS)  Seromed, Berlin, Germany 
 
Protocol: 
 
SK-UT-1 cells were plated at concentration of 5 × 104 cells/ml in 24 well dishes for 24 
hrs and then serum deprived for 48 hrs to obtain quiescent cells. On the following 
day, cells were incubated with Ang II in the presence or absence of the selective AT1 
and AT2 receptor antagonist, respectively, for 16-24 hrs. After wash with PBS, the 
cells were incubated with 100 µl of 1.5 X trypsin/EDTA solution for 3-4 min, 
suspended in 900 µl of PBS and centrifuged. The pellets were re-suspended in PBS 
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solution and 0.4%(w/v) trypan blue was added (viable cells do not take up the dye). A 
fraction of the cell mixture was pipetted onto the hemocytometer and the cells were 
counted under the light microscope. 
 
RNA isolation procedure 
 
RNA was isolated from cells and depending on the experimental protocol, prepared 
for Northern Blot or RT-PCR. This protocol describes the RNA isolation method from 
whole cells using GTC buffer according to the protocol by Chomczynski and Socchi 
(Chomczynski & Sacchin, 1987) or Trizol-reagent according to the manufacturers’ 
recommendations.  
 
Reagents: 
 
Guanidine Thiocyanate    Sigma, Deisenhofen, Germany 
N-Lauroylsarcosine     Sigma, Deisenhofen, Germany 
β-mercaptoethanol     Sigma, Deisenhofen, Germany 
Sodium acetate     Sigma, Deisenhofen, Germany 
Phenol (water saturated) 
capped with layer buffer, pH,4.2)   ICN Biomedicals, Ohio, U.S.A 
Chloroform      Merck, Darmstadt, Germany 
Isoamylalcohol     Merck, Darmstadt, Germany 
Isopropanol      Merck, Darmstadt, Germany 
Ethanol      Merck, Darmstadt, Germany 
Diethyl pyrocaronate (DEPC)   Sigma, Deisenhofen, Germany 
N-Lauroylsarcosine     Sigma, Deisenhofen, Germany 
Trizol-reagent.                                                   Gibco BRL, Eggenstein, Germany 
 
Protocol: 
 
The cells were cultured in 10 cm dishes until they reached different states of 
confluence (according to experimental requirements). The RNA was isolated using 
either the Trizol-reagent method or the GTC-buffer method. 
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Trizol-reagent method: 
2 ml of Trizol-reagent were added to each dish and incubated for 10 min at room 
temperature. The lysed cells were transferred into 1.5 ml Eppendorf tubes. 200 µl 
chloroform were added per 1 ml of Trizol-cell solution. The Eppendorf tubes were 
inverted several times and centrifuged at 13,000 rpm for 15 min, which resulted in the 
separation of the aqueous and organic phases. The upper aqueous phase containing 
the RNA was transfered into separate Eppendorf tubes. 500 µl of isopropanol were 
added and left for 15 min at room temperature. The precipitated RNA was collected 
by centrifugation at 13,000 rpm for 15 min. The RNA pellet was washed by adding 1 
ml of 75% ethanol centrifuged at 7,500 g for 5 min. Ethanol was removed and the 
pellet was left to dry for no longer than 10 min at room temperature.  
 
GTC-buffer method 
2 ml of GTC buffer (4 M guanidine thiocyanate, 5 g/l w/v, N-Lauroylsarcosine, 
0.0072% v/v, β- mercaptoethanol) were added to each dish. Repeated re-pipetting 
lysed the cells, sheared the DNA and reduced the viscosity. The cell lysate was 
transferred into separate 2 ml Eppendorf tubes and incubated in ice for 10 min. 
Sodium acetate solution (2 M, pH 4.0, 1/10 of the lysate volume) was added and the 
tubes were inverted several times. The same volume of water-saturated phenol 
solution was added and the tubes were mixed again. Then, 
chloroform/isoamylalcohol (49:1, 1/10 volume of the original lysate volume) was 
added and mixed by inverting the tubes several times. After incubation for 15 min in 
ice bath, the solutions were separated by centrifugation (12,000 g for 20 min at 4°C). 
Upper phase containing the RNA was transferred into a 2 ml Eppendorf tube. The 
RNA was precipitated by adding of isopropanol (the same volume) and keeping the 
tubes in a refrigerator at -20°C for 30 min. The RNA was collected by centrifugation 
(12,000 g for 20 min at 4°C). The RNA pellets were washed with 1 ml 100% ethanol 
followed by centrifugation (12,000 g, 10 min, at 4°C). Ethanol was removed and 
discarded. 1 ml of 75% ethanol was added and the tubes were centrifuged again 
(7,500 g, 10 min, 4°C). Ethanol was removed and the pellet was left to dry for no 
longer than 10 min at room temperature.  
 
The following steps are the same for both methods. 
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RNase free water was added (50 - 100 µl). An aliquot of 2 µl was taken for the 
determination of the RNA quantity and quality using a spectrophotometer. For this 
purpose, 2 µl of RNA solution were diluted with 198 µl of pure water and transferred 
to a crystalline cuvette to measure the RNA content. 
An optical density (OD)260nm value of 1 represents 40 µg of RNA/ml and an 
OD260:OD280 ratio of 1.6 to 2.0 indicates a high quality grade of the RNA. The RNA 
was stored at -80°C until it was used for Northern Blot or reverse transcription (see 
appropriate sections). 
 
Northern Blot and hybridization 
 
Northern Blotting and hybridization are used to determine the quality, quantity and 
size of the isolated RNA. This protocol describes the preparation of a RNA gel, the 
transfer of the RNA from the gel to a nylon membrane by a capillary blotting 
procedure and subsequently the hybridization of a radio-labeled cDNA probe to its 
corresponding RNA sequence fixed on the membrane. 
 
Reagents: 
 
Agarose      Promega, Mannheim, Germany 
Hybond-N; nylon membrane:   Amersham International plc 
Buckinhamshire, UK 
10 mg/ml ethidium bromide   Sigma, Deisenhofen, Germany 
2.5 mg/ml bromophenol blue   Sigma, Deisenhofen, Germany 
Rapid-Hyb buffer     Amersham International plc 
Buckinhamshire, UK 
Random prime labelling system   Amersham International plc 
(rediprimeTMII)     Buckinhamshire, UK 
Scientific imaging film, Biomax MS  Eastman Kodak Company, 
Rochester NY, USA 
3 MM Whatman chromatography paper  Biometra GmbH, Göttingen, Germany 
37% formaldehyde     Sigma, Deisenhofen, Germany 
10 X MOPS running buffer (pH 7.0):  
200 mM 3-(N-morpholino) propane-sulphonic acid, 80 mM sodium acetate, 10 mM 
EDTA (final pH 7.0) 
  
 
32
RNA loading buffer :  
10 µl formamide, 4 µl formaldehyde, 3 µl 10 X MOPS buffer 
20 X SSPE:  
3.6 M NaCl, 0.2 M NaH2PO4 (pH 7.4), 0.2 M EDTA (final pH 7.4) 
Orange dye :      Sigma, Deisenhofen, Germany 
0.01 M EDTA (pH 7.0), 0.05 mM Ficoll 400, 1% orange 
 
Protocol: 
 
A mixture of 73.3 ml distilled water and 1.0 g agarose was boiled in a microwave. 
Afterwards, the gel solution was cooled to 65°C and 16.7 ml of 37% formaldehyde 
and 10 ml of 10 X MOPS were added. The solution was thoroughly swirled and 
poured into a gel tray. A comb was placed into the gel and left to solidify for at least 
30 min at room temperature and then 1 hr at 4°C. After the polymerization, the gel 
was placed into the electrophoresis apparatus submerged in 1 X MOPS 
electrophoresis buffer. The comb was then carefully removed. 
Meanwhile, 10-20 µg of RNA samples had been dried previously in a speedvac 
centrifuge and re-suspended in 10 µl of DEPC water. 17 µl of RNA loading buffer 
were pipetted onto each RNA sample, mixed and briefly centrifuged. The loading 
buffer/RNA solution mixture was incubated at 68°C for 5 min and chilled in ice for 5 
min. Prior to loading, 4 µl of orange (1/10) dye was added to the mixture. After 
loading, the gel was run at 18 mA for 17.5 hrs (or 60 V for 6 hrs). 
On the following day, the gel was stained in 0.5 µg/ml ethidium bromide 1 X MOPS 
buffer for 30 min and de-stained with 1 X MOPS for 30 min. The gel was washed 
with 3 different buffers for 30 min on a shaker at room temperature. The following 
buffers, all prepared in DEPC water, were used: NaOH-NaCl (50 mM NaOH, 10 mM 
NaCl), 0.1 M Tris-HCl (pH 7.4) and in 20 X SSPE. After taken a photograph of the 
gel, the gel was inverted and placed upon a wick covered with one piece of 3MM 
Whatman chromotography paper, which was set up in a tray containing 20 X SSPE 
solution. A single nylon membrane sheet, cut to the exact gel size and pre-wetted 
first in DEPC water and then in 20 X SSPE for at least 5 min, was placed upon the 
gel and oriented by one corner cutting. 3 - 5 pieces of 3 MM Whatman 
chromotography papers of the same size were placed on the top followed by a stack 
of paper towels, all cut to the exact gel size. A 500 g weight was put on the top of the 
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paper towels. The transfer of RNA from the gel to the nylon membrane was 
completed after 8-18 hrs. The contact between the sheets and the wick was carefully 
avoided by using a slim slip of Parafilm to prevent a ”short-circuit” which would have 
led to inefficient transfer of the RNA from the gel to the nylon membrane. 
On the following day, the nylon membrane blot was removed from the gel and 
prepared for hybridization. The blot was first air dried on a sheet of dry Whatman 
paper. Upon verification of the RNA quality and quantity by holding the membrane 
against ultraviolet light, the blot was prepared for hybridization. Typical for the 
eukaryotic RNA is the prominent presence of 28S- and 18S- RNA. Both types are 
clearly visible under UV light as two prominent bands. The presence of a smear 
rather than two distinct bands indicates the loss or total degradation of the RNA 
population. The density of the bands on the blot indicates the same amount of 
sample loaded. The blot was then packed with two pieces of 3 MM Whatman paper, 
and dried for 2 hrs at 80°C in an oven to fix the RNA, and stored at -80°C till 
hybridization. 
Before the hybridization, the blot was wetted in 200 ml of sterilized distilled water, 
washed in 200 ml of 5 X SSPE solution for 5 min and then placed into a glass 
hybridization tube containing 20 ml of pre-warmed (65°C) Rapid-Hyb solution. The 
tube was placed into a hybridization oven, allowing it to rotate at 65°C for at least 30 
min. During this time, a radioactive labeled cDNA probe was prepared (see section: 
synthesis of radiolabeled cDNA probe). After the pre-hybridization period, the Rapid-
Hyb solution was removed from the tube and 20 ml of fresh Rapid-Hyb solution, 
containing the radioactive probe, were added. The tube was again placed into the 
hybridization oven and left rotating at 65°C for 1 hr.  
After the hybridization period, the blot was subjected to a series of washes of 
increasing stringency, to remove non-specifically bound radioactive probe. The 
washing procedure was usually as follows: twice at 50°C for 5 min in 2 X SSPE, 
0.1% SDS, once at 50°C for 20 min in 2 X SSPE, 0.1% SDS, twice at 65°C for 20 
min in 0.3 X SSPE, 0.1% SDS. The blot was wrapped in transparent cling 
membrane, laid into a cassette a covered with a light sensitive film. The film was 
exposed at -80°C for 1 day, 3 days and/or 7 days.  
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Synthesis of radio-labeled cDNA probes 
 
Several protocols exist to synthesize the radio-labeled cDNA probe. In the random 
priming method, the short DNA fragment to be labeled is first denatured and then 
mixed with oligonucleotides of random sequence in the presence of labeled 
nucleotide(s) and a DNA polymerase. These ”random oligos” anneal to 
complementary random sites on the DNA and serve as primers for DNA synthesis 
during which the label is incorporated. 
 
Reagents: 
 
Random prime labeling system    Amersham International plc, 
Buckinhamshire, UK 
RediprimeTMII     Amersham International plc, 
Buckinhamshire, UK 
[α-32P]dCTP      Amersham International plc, 
specific activity: 3000 Ci/mmol   Buckinhamshire, UK 
Rapid-Hyb buffer     Amersham International plc 
Buckinhamshire, UK 
TE-buffer (pH 8.0): 
10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0) 
 
Protocol: 
 
The Random prime labeling system was used to generate radioactive labeled DNA 
probes and the procedure was performed according to the manufacturers´ 
recommendations. 2 µl of target DNA (see the section: preparation and 
transformation of competent cells) prepared as described elsewhere (see the 
section: plasmid DNA preparation, DNA precipitation, gel electrophoresis and gel 
isolation) were added into 43 µl of TE buffer in a 1.5 ml Eppendorf tube and boiled 
for 5 min in a water bath and left to cool in ice for at least 10 min. The denatured 
cDNA solution was transferred into the tube containing labeling reaction 
(oligonucleotides of random sequence in the presence of labeled nucleotide(s) and a 
DNA polymerase). 5 µl of [α- 32P] was added to the cDNA mixture and pipetted up 
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and down and the solution was briefly mixed. The reaction mixture was incubated at 
37°C for 10 min and then 5 µl of 0.2 M EDTA were added. The mixture was boiled 
for 5 min then chilled in ice to terminate the reaction. The non-bound radioactivity [α- 
32P] was separated from the labeled DNA by chromatography. The labeled cDNA 
probe was added into 20 ml fresh Rapid-Hyb buffer used for blotting (see section: 
Northern Blott and hybridization). 
 
Target DNA preparation and transfection into competent cells 
 
This protocol describes the preparation of target DNA for Northern Blot and 
transfection the DNA fragment into competent cells by original TA cloning kit. The 
PCR product inserted into the pCR 2.1 plasmid vector and transformed into One 
ShotTM cells by heat shock which allows these cells to accept foreign DNA. Individual 
recombinant plasmids were analyzed by restriction mapping for orientation. The 
correct recombinant plasmid was then purified for further experiments. 
 
Reagents: 
 
Original TA Clonging Kit 
(containing: 10 X Ligation buffer, T4 DNA Ligase, SOC medium, INVαF‘ one shot 
competent cells)     Invitrogen, Groningen,  
The Netherlands  
Luria-Bertani (LB) broth    Sigma, Deisenhofen, Germany 
LB agar (Lennox L agar)    Sigma, Deisenhofen, Germany 
 
Protocol: 
 
All medium and buffers used in this protocol were either autoclaved or filter 
sterilized. The procedure was performed according to manufacturers’ 
recommendations. 
Ten µl of fresh PCR product sample (usually 35 cycles, see section of PCR) sample 
were purified on 1-2 % of agarose gel electrophoresis, separated using a spin 
column (see the section, DNA gel electrophoresis and gel isolation). Ten µl of 
ligation reaction solution containing the PCR product, were prepared as follows: Five 
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µl of sterile water, 1 µl of 10 X ligation buffer, 2 µl of pCR vector (25 ng/µl), 1 µl of 
fresh PCR product and 1 µl of T4 DNA ligase. The reaction solution was incubated 
at 14°C overnight for transformation.  
Vials containing 50 µl of frozen INVαF‘ competent cells (One Shot competent cells) 
were thawed on ice. 2 µl of 0.5 M β-mercatoethanol were pipetted into each vial and 
gently mixed. Then, 2 µl of ligation reaction solution were directly pipetted into the 
vials containing INVαF‘ competent cells and gently mixed. After incubation on ice for 
30 min, the cells were shock-heated for 30 sec at exactly 42°C and cooled on ice for 
2 min. 250 µl of SOC medium (at room temperature) were added to each vial, 
incubated at 37°C for exactly 1 hr at in an incubator and then cooled on ice. 50 or 
100 µl of INVαF‘ cells were spread onto LB agar plates containing 50 µg/ml of 
ampicillin. The plates with the spread cells were inverted and incubated at 37°C in 
an incubator for at least 18 hrs and then at 4°C for additional 2-3 hrs. 5-10 pieces of 
colonies from different areas of the plate were chosen and analyzed for the 
orientation of the insert in the plasmid.  
 
Minipreps of plasmid DNA 
 
Plasmids are able to replicate in bacterial cultures grown in the presence of the 
selective antibiotic. This protocol describes the plasmid DNA recovery procedure. 
The procedure was performed according to the manufacturers’ recommendations. 
 
Reagents: 
 
Qiagen plasmid combi kit    Qiangen GmgH, Hilden, Germany 
LB broth      Sigma, Deisenhofen, Germany 
 
Protocol: 
 
A single bacterial colony from an overnight culture grown on an agar plate was 
transferred to 5 ml LB medium containing ampicillin (50 µg/ml). The culture was 
incubated with shaking (250 rpm) at 37°C overnight. On the following day, the 
bacteria were collected by a 5 min spin at 3,000 rpm. The bacteria pellet was 
resuspended in 300 µl of buffer P1 (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 
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µg/ml RNase A). 300 µl of buffer P2 (200 mM NaOH, 1% SDS) were added and the 
mixture was gently swirled for 5 min to lyse the cells. Additional 300 µl of buffer P3 
(3.0 M potassium acetate, pH 5.5) were added which caused immediately 
precipitation of proteins. The mixture was rapidly but gently mixed and immediately 
centrifuged at 13,000 rpm at 4°C for 10 min. The supernatant was applied to the tips, 
which had been equilibrated with 1 ml of buffer QBT (0.75 M NaCl; 50 mM MOPS, 
pH 7.0; 15% ethanol; 0.15% Triton X-100) and emptied by gravity flow. The tips 
were 4 times washed with 1 ml of buffer QC (1.0 M NaCl; 50 mM MOPS, pH 7.0; 
15% ethanol). The DNA in the tip was eluted by 0.8 ml buffer QF (1.25 M NaCl; 50 
mM Tris-HCl, pH 8.5; 15% ethanol) and precipitated with 0.7 volumes of 
isopropanol. After centrifugation at 10,000 rpm for 30 min and wash with 1 ml of 70% 
ethanol, the DNA was resuspended in TE buffer (10 mM Tris-Cl, pH 8.0; 1 mM 
EDTA). For spectrophotometrical analysis, 2 µl of DNA stock solution were pipetted 
into 198 µl of water and transferred to a crystalline cuvette. An OD260 nm value of 1 
represents to 50 µg of DNA/ml and OD260nm:OD280nm ratio of 1.6 to 2.0 indicates a 
high quality grade of the DNA. The DNA was stored in water at -20°C . 
 
DNA restriction procedure  
 
DNA fragments isolated from plasmid were cut with appropriate enzymes and 
isolated by DNA electrophoresis. This protocol describes the restriction used through 
the research project. 
 
Reagents: 
 
DNA restriction enzyme    Gibco RBL, Eggenstein, Germany 
10 X restriction endonuclease buffer: 
100 mM Tris-HCl (pH 7.5), 100 mM MgCl2, 10 mM DTT, 1 mg/ml BSA, 0, 0.5, 1.0, 
1.5 M NaCl      Gibco RBL, Eggenstein, Germany 
(NaCl concentration vary depending on the enzyme used. These four different 
concentrations cover most commercially available restriction enzyme). 
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Protocol: 
 
DNA, usually 2 µg, was cut in a reaction volume of 25 µl at 37°C for 1 hr or overnight 
in the presence of 1 X restriction endonuclease buffer. The reaction was terminated 
by a phenol:chloroform extraction (1:1) and ethanol precipitation. The fragments of 
DNA was checked with DNA gel electrophoresis (see section: DNA gel 
electrophoresis and gel isolation) and the appropriate DNA was isolated from the gel 
and used for Northern Blot. 
 
DNA precipitation, gel electrophoresis and gel isolation 
 
DNA fragments were run on an agarose gel to analyze their quality and size. 
Additionally, once DNA fragments were separated on a gel, it was possible to isolate 
them for subsequent radio-labeling or cloning procedures. This protocol describes 
the preparation of a DNA gel and electrophoresis, and the isolation procedure of a 
single DNA from a gel. 
 
Reagents: 
Agarose      Promega, Mannheim, Germany 
gel extraction kit     Qiagen GmbH, Hilden, Germany 
10 mg/ml ethidium bromide   Sigma, Deisenhofen, Germany 
TBE buffer ( 1 liter, 10 X stock solution):  
108 g Tris base, 55 g boric acid, 40 ml of 0.5 M EDTA (pH 8.0) 
Loading buffer (10 X): 
50% (v/v) glycerol, 0.1 M EDTA (pH 8.0), 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol 
 
Protocol: 
 
To 100 ml of 1 X TBE, 1.0 g of agarose was added and brought to boil in a 
microwave. The boiling solution was thoroughly swirled and poured into a prepared 
gel tray. A comb was inserted. The gel was left to polymerize and kept at 4°C at 
least 1 hr before being used. The gel was placed into the electrophoresis apparatus  
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and submerged in 1 X TBE electrophoresis buffer after which the comb was carefully 
removed. 
Prior to a gel run, the DNA dissolved in ultra-pure water was mixed with 10 X loading 
buffer. The mixture was loaded into the gel slot and subjected to an electrical field of 
90 V for at least 1 hr. The gel was then stained with ethidium bromide (5 µg/ml) for 
20 min. The DNA fragments were visualized under ultraviolet light and photographed 
using a video documentation system. 
DNA fragments were isolated from the gel using a commercially available kit. The 
procedure was performed according to the manufacturers’ recommendations. 
Briefly, the band containing the DNA fragment of interest was cut from the gel under 
the UV and placed in an Eppendorf tube. Solubilization buffer was added and the 
mixture was incubated at 50°C for 10 min. The dissolved gel mixture was transferred 
to a spin column designed to trap DNA on a glass fibre filter. The filter was washed 
twice by adding 700 µl of provided buffer followed by centrifugation step of 13,000 
rpm for 1 min. After the washing procedure, 50 µl of ultra-pure water were added to 
the glass fibre filter which was left at room temperature for 5 min to elute the DNA. 
The column was spun at 13,000 rpm for 1 min and the DNA was recovered in a 
collection tube. The purified DNA could be used immediately for radio-labeling or 
cloning procedures. 
 
Reverse transcription reaction 
 
The enzyme reverse transcriptase was used to generate DNA molecules from RNA 
molecules. Like the DNA polymerases, this enzyme can build a complementary 
nucleic acid strand on a template by adding nucleotides to a hybridized short DNA 
fragment or primer.  
 
Reagents: 
 
Total RNA isolated from whole cells (for procedure see section: RNA isolation) 
Superscript reverse transcription kit  Gibco BRL, Eggenstein, Germany 
10 X reverse transcription buffer:  
200 mM Tris-HCl (pH 8.4), 500 mM KCl 
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Protocol: 
 
To 5 µg of total RNA, 1 µl of oligo(dT) primers (0.5 µg/µl) and DEPC treated water 
were added up to a volume of 12 µl. The mixture was heated to 70°C for 10 min and 
cooled on ice for at least 1 min. Meanwhile, a stock solution of 2 µl 10 X reverse 
transcription buffer, 2 µl of MgCl2 (25 mM), 1 µl of nucleotides (10 mM each) and 2 µl 
DTT (0.1 M) was prepared. The prepared mixture was pipetted into the 
oligo(dT)/RNA solution which was incubated at 42°C for 5 min. Following the brief 
incubation period, 200 units of Superscriptase for each sample were added and the 
tubes were incubated at 42°C for additional 50 min. The reaction was terminated by 
heating the tubes to 70°C for 15 min and by subsequent cooling on ice. To destroy 
the RNA template, 2 units of RNase H were added to the reaction mixture, which was 
then incubated at 37°C for 20 min. Finally, the cDNA mixture was stored at -20°C 
until use in the PCR. 
 
Polymerase chain reaction (PCR) 
 
The PCR is a rapid procedure for an in vitro enzymatic amplification of a specific 
segment of DNA. A typical PCR mixture contains the target DNA, the 
oligodeoxynucleotides (short DNA fragments encoding for the extreme ends of the 
target DNA) in much higher concentration than the target DNA, free nucleotides and 
a heat stable DNA polymerase with suitable buffer components. The mixture is 
heated to 95°C for 1 min to denature the target DNA followed by a cooling step to 55-
65°C for 1 min to allow the oligodeoxynucleotides to hybridize into their complete 
DNA sequences. The mixture is brought to 72°C, which is the optimum temperature 
for the Taq polymerase to extend the hybridized oligodeoxynucleotides. When the 
synthesis is complete the mixture is heated further to 95°C to melt the synthesized 
DNA duplexes. When the temperature is lowered, another round of synthesis can 
take place because an excess of oligodeoxynucleotides is still present. The cycle of 
melting, hybridization and synthesis is repeated many times. At each round the 
number of copies of the sequence of interest is doubled and therefore the number of 
copies increases exponentially. A single target DNA molecule provides 2n copies, 
with n being the number of cycles. 
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Reagents 
 
Taq polymerase     Gibco BRL, Eggenstein, Germany 
Nucleotide(s)     Roche, Mannheim, Germany 
human AT1 receptor primers   Pharmacia Biotech, Germany 
human AT2 receptor primers   Pharmacia Biotech, Germany 
human calponin primers    Pharmacia Biotech, Germany 
human SM22 primers    Pharmacia Biotech, Germany 
rat iNOS primers     Pharmacia Biotech, Germany 
rat eNOS primers     Pharmacia Biotech, Germany 
rat nNOS primers     Pharmacia Biotech, Germany 
rat AT1 receptor primers    Pharmacia Biotech, Germany 
rat AT2 receptor primers    Pharmacia Biotech, Germany 
 
Protocol 
 
The following components were pipetted into an Eppendorf tube: 5 µl 10 X PCR 
buffer, 2 µl of MgCl2 (50 mM), 4 µl of nucleotides (final concentration: 0.125 µM 
each), 1 µl of primers (10 mM each), 0.5 µl Taq (5 µg/µl), 1 µl of cDNA stock solution 
and ultra-pure water up to 50 µl. 
The mixture was placed in a thermo cycler and heated to 95°C for 5 min and 
submitted 35-times to 95°C for 30 sec, 56°C (temperature profiles were adjusted 
depending on the specific primer sequences) for 30 sec and 72°C for 1 min. 
Following the cycle procedure, the mixture was incubated at 72°C for 7 min and then 
kept at 4°C until use. 
. 
Cytoplasma proteins isolation and measurement 
 
This protocol describes the isolation procedure of total proteins from cell plasma. 
Various protein enzyme inhibitors were used in the protocol. The total proteins were 
measured by the protein assay kit according to the manufacturers’ recommendations. 
 
Reagents: 
Aprotinin      Roche, Mannheim, Germany 
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Leupeptin      Roche, Mannheim, Germany 
TPCK       Roche, Mannheim, Germany 
Lysis buffer: 
50 mM Tris-HCl (pH 8.0); 0.25 M NaCl; 0.5% NP-40; 1 mM PMSF; 1 µg/ml aprotinin; 
1 µg/ml leupeptin; 20 µg/ml TPCK 
Bio-Rad protein assay    BIO-RAD, Copenhagen, Denmark 
 
Protocol: 
 
To obtain cell pellets, the cells were harvested with 800 µl of PBS once and 
centrifuged at 3,000 rpm for 5 min. The cell pellets were re-suspended with 200 µl of 
lysis buffer on ice for 30 min. After centrifugation at 13,000 rpm for 20 min the 
supernatant containing crude proteins was transferred into another Eppendorf tube 
and stored at -80°C till further analysis. 
The Bio-Rad reagent was diluted with distilled water as 1:5. The BSA stock solution 
was diluted into 3 different working solutions (0.1; 0.2; 0.4 µg/µl) with distilled water. 
The sample proteins were diluted 1:50 with distilled water. 20 µl of diluted sample 
proteins or standard proteins were transferred into 1 ml of Bio-Rad reagent solution 
and incubated at room temperature for 10 min. OD595nm of protein standards and 
samples were measured by spectrophotometer. 
 
SDS Polyacrylamide gel electrophoresis of proteins (SDS-PAGE) 
 
The strongly anionic detergent sodium dodecyl sulfate (SDS) is used in combination 
with a reducing agent. The proteins are heated to denature before they are loaded on 
a gel. The denatured polypeptides bind SDS and become negatively charged. 
Because the amount of SDS bound is proportional to the molecular weight of the 
polypeptides and is independent of their sequence, SDS-polypeptide complexes 
migrate through polyacrylamide gels to the anode according to the size of the 
polypeptide. By using markers of known molecular weight, it is possible to estimate 
the molecular weight of the protein. 
 
Reagents: 
Ammonium persulfate (APS)(10%)  Sigma, Deisenhofen, Germany 
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TEMED      Roche, Mannheim, Germany 
Polyacrylamide solution (PAA)   Sigma, Deisenhofen, Germany 
(acrylamide:bisacrylamide 29%:1%) 
Separating gel solution: 
10 % PAA, 375 mM Tris-HCl (pH 8.8); 0.1 % SDS 
Stacking gel solution: 
5 % PAA; 125 mM Tris-HCl (pH 6.8); 0.1 % SDS 
5 X sample buffer: 
60 mM Tris-HCl (pH 6.8), 2 % SDS, 14.4 mM 2-mercaptoethanol, 25 % glycerol, 0.1 
% bromophenol blue. 
Electrophoresis buffer: 
275 mM Tris-HCl (pH 8.3); 200 mM glycine; 0.1 % SDS 
 
Protocol: 
 
Immediately before use, APS (final concentration is 0.1% v/v) and TEMEP (final 
concentration is 0.01%) were added to the gel solution. Upon preparation, the 
separating gel solution was pipetted between the assembled glass plate sandwich 
and covered with a layer of water and left to polymerize for 30 to 45 min. 
Subsequently, the water layer was removed and the prepared stacking gel solution 
was poured on the top of the polymerized separating gel. The comb was inserted and 
the gel was left to polymerize for additional 30 min. The prepared gel was assembled 
into the electrophoresis apparatus and submerged in electrophoresis buffer. The 
protein aliquots were diluted with distilled water to 20 µl and 5 µl of 5 X sample buffer 
were added. The mixture was incubated at 95°C for 10 min and then cooled on ice. 
The denatured samples were loaded onto the gel and subjected to electrical field of 
150 V for 65 min. Upon completion of the gel run, proteins were transferred onto 
methanol activated nitrocellulose filter. 
 
Western Blot  
 
Virtually all western blots are carried out in two stages: an unlabeled antibody 
specific to the target protein is first incubated with the nitrocellulose filter containing 
the proteins in the presence of blocking solution. The filter is then washed and 
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incubated with a second antibody that is conjugated directly with horseradish 
peroxidase. After further washing, the antigen-antibody-antibody complexes on the 
nitrocellulose filter is located by an in situ enzymatic reaction resulting in the 
production of light, which can be detected using a light-sensitive film. 
 
Reagents: 
 
Monoclonal human anti-Calponin antibody Sigma, Deisenhofen, Germany 
Peroxidase-linked antimouse IgG  Amersham, Freiburg, Germany 
ECL western blot detection reagents  Amersham, Freiburg, Germany 
 
Protocol: 
 
After incubation in blocking solution and briefly wash with 1 X TTBS, the membrane 
was immediately put into in a sealed box and incubated in a solution containing the 
primary antibody 5% of non-fat dried milk on a platform shaker at 4°C overnight. The 
membrane was washed three times with 1 X TTBS (15 min X 1 time and 5 min X 2 
times) and incubated with the peroxidase-linked second antibody in a solution 
containing 2% of non-fat dried milk at room temperature for 1 hr. After the membrane 
had been transferred into an another tray, it was washed 5 times with 1 X TTBS (15 
min X 1 time and 5 min X 4 times). All next steps were carried out in a dark room. 
Equal volumes of the detection solution 1 and the detection solution 2 were mixed 
together given a sufficient volume of the detection reagent to cover the membrane. 
The membrane was incubated in the detection reagent for 1 min at room temperature 
and then the excess of the detection reagent was drain off. The membrane was 
wrapped in transparent foil, fixed in the film cassette and exposed to  
autoradiography film for 3-5 min (in same cases for 10 min). The films were 
developed. The density of the bands correspond to the amount of proteins in the 
membrane. 
  
Staining for apoptosis (TUNEL method) 
 
Commercially available "In Situ Cell Death Detection Kit" allows the detection of 
cleaved DNA strands which are characteristic for apoptosis. DNA strand breaks can 
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be identified by labeling free 3‘-OH termini with modified nucleotides incorporated by 
an enzymatic reaction. Free 3‘-OH termini were elongated with fluorescein labeled 
nucleotides by terminal deoxynucleotidyl transferase (TDT) in a template- 
independent fashion. These nucleotides were in turn detected by an antibody 
conjugated with horseradish peroxidase. After a substrate reaction, apoptotic cells 
became stained and were detected by light microscopy. 
 
Reagents: 
 
In Situ Cell Death Detection Kit   Roche,Mannheim,Germany 
TUNEL (TDT-mediated dUTP nick end labeling  
mixture: modified nucleotides, TDT, anti-fluorescein antibody) 
DNase I (RNase free)    Roche, Mannheim, Germany 
TUNEL dilution Buffer    Roche, Mannheim, Germany 
DAB Substrate     Roche, Mannheim, Germany 
(10 X DAB Metal Enhanced Substrate set, DAB Peroxide Buffer) 
Paraformaldehyde     Sigma, Deisenhofen, Germany 
H2O2       Sigma, Deisenhofen, Germany 
Permeabilization solution: 
0.2 % Triton X-100 in 0.1 % sodium citrate 
Peroxidase dilute buffer (POD buffer)   Roche, Mannheim, Germany 
 
Protocol: 
 
The procedure was performed according to the manufacturers’ recommendation. 
Briefly, the cells were plated in the 24 well plate for 72 hours. The treated cells were 
washed with PBS, dried by air and fixed using 4% of paraformaldehyde (pH 7.4) for 
30 min at room temperature. The cells were then incubated in 0.3 % H2O2 in 
methanol for 30 min at room temperature and kept under permeabilisation solution 
for 15 min at room temperature after washing wish PBS once. The cells serving as 
the positive control were pre-treated with DNase (100 µ/ml) at 37°C in a humidified 
chamber. All cells were then incubated in 50 % TUNEL mixture for 1 hr at 37°C in 
humidified chamber. Cells serving as the negative control were incubated with 50% 
TUNEL mixture without labeling enzyme (TDT). After rinsed with PBS three times, 
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the cells were incubated with converter horseradish peroxidase for an additional 1 hr 
at 37°C in a humidified chamber. The cells were then treated with 1 X DAB-substrate 
diluted with POD buffer and the reaction was allowed to run for 8 min at room 
temperature. Each incubation step was proceeded by three washing steps using 
PBS. The cells were photographed using light microscope. 
 
Apoptotic DNA ladder  
 
Cleavage of DNA in the cell is one of the hallmarks of apoptosis. To detect the 
apoptotic cells, cleaved DNA fragments can be analyzed using agarose gel after 
purification of DNA from cultured cells. Cells are lysed in binding buffer, the solution 
is transferred to a filter tube with glass fibre fleece and centrifuged. Nucleic acids 
bind specifically to the surface of glass fibres in the presence of chaotropic salts. 
Residual impurities are removed by a wash step and subsequently DNA is eluted 
with elution buffer. 
 
Reagents: 
 
Apoptotic DNA Ladder Kit    Roche, Mannheim, Germany 
Agarose      Promega, Mannheim, Germany 
Ethidium bromide     Sigma, Deisenhofen, Germany 
Isoproponal      Sigma, Deisenhofen, Germany 
 
Protocol: 
SK-UT-1 cells were plated in 10 cm dishes and left to growth until 70% confluence. 
After the cells had been treated with various ligands and antagonists, they were 
harvested with 1.5 X trypsin/EDTA and re-suspended in 1 ml PBS solution. 200 µl of 
the cell-PBS solution (about 2 X 106 cells) were lysed in 200 µl lysis buffer during a 
10 min incubation at room temperature. 100 µl of 100 % of isopropanol were used to 
precipitate the DNA and the resulting solution was transferred into filter tubes. After 
several washing steps, the DNA bound to the filter was eluted using elution buffer. 
Three µg of purified DNA from each sample was loaded to 1 % agarose gel (see 
section DNA precipitation, gel electrophoresis and gel isolation) and the gel was run 
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at 75 V for 4 hr. The apoptotic cells from the kit served as the positive control. DNA 
ladder was analyzed under UV and photographed for documentation. 
 
Differentiation assay: Cell morphology 
 
The outgrowth of axons and dendrites (together known as neurites) is a fundamental 
morphological event associated with neural development and differentiation. 
Therefore, the number of outgrowth neurites of certain length together with cell 
numbers represents an excellent marker for the cell differentiation. For the purpose 
of quantification, it seems to be useful to define at least three groups of neurites 
according to their lengths.  
 
Reagents: 
 
Collagen A (5 mg/ml)    Seromed, Berlin, Germany 
NGF       Sigma, Deisenhofen, Germany 
Nωnitro-L-agrinine methyl ester (L-NAME) Sigma, Deisenhofen, Germany 
8-bromoguanosine 3’:5’-cyclic monophosphate  
(8-bromo-cGMP)      Sigma, Deisenhofen, Germany 
Sodium nitroprusside (SNP)   Sigma, Deisenhofen, Germany 
 
Protocol: 
 
PC12 W cells in normal medium were planted at 1.4 X 10 3/cm2 into the 10 cm 
dishes, which were pre-treated with collagen A : PBS (1:6) solution for 24 hrs. On the 
next day, the cells were serum deprived for 48 hrs to get quiescence. From day 4 to 
day 9 after planting, the cells were daily treated with desired tested substances 
(differentiation-inducer). The starve medium was changed daily. After 6 days of 
treatment, the cells were rinsed with PBS, and five randomly selected areas per one 
culture dish were photographed by phase-contrast microscopy. The obtained slides 
were projected on 4A papers and the cell numbers and neurite lengths, were marked 
on the papers for quantitative evaluation. Cell clusters (> 15 cells) were excluded. 
Outgrowth neurites were classified into three groups according to their length: small 
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neurites ( <10mm, ≅ < 5um), medium neurites (10-20mm, ≅ 5-10 um) and large 
neurites (> 20 mm, ≅ > 10 um), and expressed as the numbers of neurite/100 cells 
 
Data presentation 
 
The results of cell counting procedure and thymidine assay in the proliferation study 
were representative for three to six separately performed experiments. For the cell 
counting, the data points presented per experiment correspond to an average ± SEM 
of n=6 or 12. For the thymidine assays, the data points presented per experiment 
correspond to an average ± SEM of n=4. The data of PCR and western blot for 
differentiation as well as of TUNEL and DNA ladder for apoptosis were 
representative for at least three separately performed experiments. Photographs 
from PCR were quantified using the imaging software. The data in the differentiation 
study for PC12W cells were obtained from at least two independent experiments and 
all were presented as means ± SEM. The statistical analysis was performed using 
one-way analysis of variance (AVOVA) followed by appropriate post-hoc tests. 
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APPENDIX to Material and Method 
 
β - Actin Primer sequences: 
 
Upper primer:   5‘ – ATG-GAT-GAT-GAT-ATC-GCC-GCG  3‘ 
Lower primer:   5‘ – CAT-GAA-GCA-TTT-GCG-GTG-GAC-GAT-GGA-GGG-GCC  3‘ 
 
Human AT1 receptor primer sequences: 
 
Upper primer:   5‘ – GCA TTG ATC GAT ACC TGG CT – 3‘ 
Lower primer:   5‘ – TTA CAT TAT CTG AGG GGC GG – 3‘ 
 
Human AT2 receptor primer sequences: 
 
Upper primer:   5‘ – GCT TGT GAA CAT CTC TGG CA – 3‘ 
Lower primer:   5‘ – TTC ATT AAG GCA ATC CCA GC – 3‘ 
 
Human calponin primer sequences: 
 
Upper primer:   5‘ – AAA CAG GTG AAC GTG GGA G – 3‘ 
Lower primer:   5‘ – TAG TTG TGT GCG TGG TGG TT – 3‘ 
 
Human SM22 primer sequences: 
 
Upper primer:   5´ – ACA AGT CTT CAC TCC TCC CTG C-3’ 
Lower primer:   5´ – TCA AAG AGG TCA ACA GTC TGG A-3’ 
 
Rat Zincfinger homoeodomain enhancer binding protein - primer sequences: 
 
Upper primer:   5‘ – CAC ATT AAG TAC CGC CAT GAGA 
Lower primer:   5‘ – GTT GTG CCA TCC TGA TCA ACTA 
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Rat iNOS primer sequences 
 
Upper primer:   5‘ – GTT TTC TCC TTC CAC CGT GTA G – 3’ 
Lower primer:   5‘ – CAG GAG GCA GAG AAA GAC AGA T – 3’ 
 
Rat eNOS primer sequences 
 
Upper primer:   5‘ – CCG CAC TTC TGT GCC TTT GCT C – 3’ 
Lower primer:   5‘ – GCT CGG GTG GAT TTG CTG CTC T – 3’ 
 
Rat nNOS primer sequences 
 
Upper primer:   5‘ – AGA AGG AAC AGT CCC CTA CCT C – 3’ 
Lower primer:   5‘ – ACA GAT GTA GTT GAA CAT GCC G – 3’ 
 
 
Rat AT1 receptor primer sequences: 
 
Upper primer:   5‘ – CAC GTG TCT CAG CAT CGA TCG – 3‘ 
Lower primer:   5‘ – TGG CCA AGC CAG CCA TTA G – 3‘ 
 
Rat AT2 receptor primer sequences: 
 
Upper primer:   5‘ – AGT TCC CCT TGT TTG GTG TAT GG – 3‘ 
Lower primer:   5‘ - CAT TAA GGC AAT CCC AGC AGA C – 3‘ 
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Results (section I) 
 
Expression of Ang II receptor subtypes in human leiomyosarcoma cells 
 
In the first study, the expression of AT1 and AT2 receptors in this cell line was 
determined by RT-PCR. The data from RT-PCR shows that both angiotensin 
receptors subtypes were expressed in these cells (Fig 1-1). In the presence of growth 
factors in the medium, the expression of the AT2 receptor was much weaker 
compared to that obtained in cells cultured in serum deprived medium for 48 hrs. 
 
(A) 
 
 
 
 
                                 3 mM MgCl2            2.5 mM MgCl2           2.0 mM MgCl2 
(B) 
 
 
 
 
 
Fig 1-1. Expression of AT1 and AT2 receptors in SK-UT-1 cells. Total RNA was 
isolated from SK-UT-1 cells cultured either in normal medium or in starve medium. 5 
µg of total RNA were transcripted into cDNA and equal amounts of cDNAs were used 
for PCR with specific human AT1 and AT2 receptor primers, following 35 and 50 
cycles respectively. Human umbilical SMC served as a positive control for the AT1 
receptor PCR. Human genomic DNA was used as a positive control for the AT2 
receptor PCR. 15 µl of each PCR product were loaded on 1.2 % agarose gel and run 
at 90 V for 100 min. (A) PCR was performed using different concentration of MgCl2 
for the AT2 receptor. The AT2 receptor was identified by the product of 582 bp. (B) 
PCR for the AT1 receptor was identified by the product of 669 bp. 
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Effects of Ang II on the proliferation of quiescent SK-UT-1 cells  
 
To investigate whether Ang II has any effect on the proliferation of leiomyosarcoma 
cells, SK-UT-1 cells (5 x 104 per well) were cultured in a 24 well-plate in normal 
medium containing 10% iFCS, 1% penicillin/streptomycin (100 IU/ml, 100 µg/ml) and 
2 mM L-glutamine. After 24 hrs, the medium was changed, and the cells were kept 
serum deprived for 48 hrs. For the cell counting, quiescent cells were stimulated with 
Ang II (10-7 M) in the presence or absence of angiotensin receptor antagonists, 
losartan (10-5 M) and PD123177 (10-6 M) for 16 to 20 hrs (overnight). Fig 1-2 shows 
that overnight treatment of quiescent SK-UT-1 cells with Ang II in the presence or 
absence of the AT1 or the AT2 receptor antagonists did not significantly change the 
number of cells. It can be concluded that in the absence of growth factors, stimulation 
of angiotensin receptors has no effect on the proliferation of leiomyosarcoma cells. 
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Fig 1-2. Effects of Ang II on the proliferation of quiescent SK-UT-1 cells. SK-UT-
1 cells were planted in normal medium for 24 hrs to allow them to attach to the 
bottom of the dishes. Then the cells were serum deprived for 48 hrs to obtain 
quiescence. Ang II (10-7 M); Ang II (10-7 M) + losartan (los, 10-5 M); Ang II (10-7 M) + 
PD123177 (PD,10-6 M) or Ang II (10-7 M) + losartan (10-5 M) + PD123177 (10-6 M) 
were added to the cells cultured in serum deprived medium. Cells were harvested by 
trypsin/EDTA solution and counted in a hemocytometer. The presented data are from 
a single experiment and representative of four independent experiments. Values 
represent means ± SEM of n=12. 
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Effect of Ang II on the proliferation of SK-UT-1 cells in the presence of growth 
factors 
 
It has been suggested that the effect of Ang II on the cell proliferation may require 
growth factors. Cell counting and 3H thymidine incorporation experiments were 
carried out to investigate whether Ang II induces proliferation of SK-UT-1 cells in the 
presence of growth factors. Cells, 5 x 104/well, were cultured in 24 well-plates in 
normal medium containing 10% iFCS for 24 hrs and then 48 hrs in starved medium. 
The cells were then incubated with Ang II (10-7 M) in the presence or absence of the 
AT1 and AT2 receptor antagonists, losartan (10-5 M) and PD123177 (10-6 M) 
respectively for 16 to 20 hrs (overnight) in normal medium containing 10% iFCS or 
1% insulin transferrin selenium (ITS). Cell counting and 3H-thymidine incorporation 
(Fig 1-3 and Fig. 1-4) show that stimulation of AT1 or AT2 receptors did not 
significantly influence the growth factor-induced cell proliferation. 
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Fig 1-3. Effects of Ang II on the proliferation of SK-UT-1 cells cultured in the 
presence of growth factors. Quiescent SK-UT-1 cells cultured in medium 
containing (A) 10% iFCS or (B) 1% ITS were treated with Ang II (10-7 M); Ang II (10-7 
M) + losartan (10-5 M); Ang II (10-7 M) + PD123177 (10-6 M) or Ang II (10-7 M) + 
losartan (10-5 M) + PD123177 (10-6 M) for 16-20 hrs. Cells were harvested by 
trypsin/EDTA solution and counted in a hemocytometer. The presented data are from 
a single experiment and representative of four independent experiments. Values 
represent means ± SEM of n=12. 
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Fig 1-4. Effects of Ang II on [methyl,1,2-3H]-thymidine incorporation in SK-UT-1 
cells cultured in the presence of growth factors. Quiescent SK-UT-1 cells 
cultured in medium containing (A). 10% iFCS or (B). 1% ITS were treated with Ang II 
(10-7 M); Ang II(10-7 M) + losartan (10-5 M); Ang II (10-7 M) + PD123177 (10-6 M) or 
Ang II (10-7 M) + losartan (10-5 M) + PD123177 (10-6 M) for 16-20 hrs. The presented 
data are from a single experiment and representative of four independent 
experiments. Values represent means ± SEM of n=16. 
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The AT2 receptor has been demonstrated to be abundantly expressed upon high 
confluence in primary mesangial cells derived from normotensive Wistar-Kyoto rats 
(Goto et al., 1997). To study the effect of Ang II on SK-UT-1 cells cultured upon high 
confluence conditions, the same experimental protocol was used as in previous 
experiments. Cells were cultured in 24 well plates until they reached high confluence. 
Quiescent cells were then incubated with Ang II (10-7 M) in the presence or absence 
of the AT1 and AT2 receptor antagonists, losartan (10-5 M) and PD123177 (10-6 M), 
respectively for 16 to 20 hrs (overnight) in normal medium containing 10% iFCS. Fig 
1-5 shows that Ang II had not significantly effect on proliferation of these cells.  
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Fig 1-5. Effects of Ang II on the proliferation of SK-UT-1 cells cultured upon 
high confluence. SK-UT-1 cells were cultured until they reached high confluence. 
Quiescent SK-UT-1 cells were treated with Ang II (10-7 M); Ang II(10-7 M) + losartan 
(10-5 M); Ang II (10-7 M) + PD123177 (10-6 M) or Ang II (10-7 M) + losartan (10-5 M) + 
PD123177 (10-6 M) in culture medium containing 10% iFCS for 16-20 hrs. Cells were 
harvested by trypsin/EDTA solution and counted in a hemocytometer. The presented 
data are from a single experiment and representative of four independent 
experiments. Values represent means ± SEM of n=12. 
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Taken together, these experiments clearly demonstrate that Ang II has no effect on 
the cell numbers or on the cell DNA synthesis in both, quiescent and proliferating SK-
UT-1 cells. 
 
Ang II and the expression of SM22, a differentiation marker, in SK-UT-1 cells  
 
The following experiments were aimed to study whether Ang II can induce 
differentiation in leiomyosarcomas cells. The cell were cultured in normal medium 
until 70% confluence. Quiescent cells, obtained by serum deprivation for 48 hrs, were 
treated with Ang II (10-7 M) in the presence or absence of the AT1 and AT2 receptor 
antagonist, losartan (10-5 M) and PD123317 (10-6 M), respectively, for 1, 3 and 6 hrs 
in culture medium containing 1% ITS. Total RNA was extracted using GTC buffer 
according to the protocol by Chomczynski and Sacchi. RT-PCR was carried out using 
5 µg of total RNA. Fig 1-6 (A) shows that Ang II up-regulated the mRNA level of 
SM22 in SK-UT-1 cells only when the AT1 receptor was blocked by losartan. The 
effect was completely reversed by the addition of the AT2 receptor antagonist, 
PD1231777. One hour post-treatment of Ang II alone did not up-regulate SM22 
mRNA when both receptor subtypes were stimulated by the peptide. The stimulatory 
effect of Ang II on the SM22 mRNA expression in the presence of the AT1 receptor 
antagonist could be detected only 1 hr after the peptide treatment. Three and 6 hrs 
post-stimulation with Ang II SM22 mRNA levels were equally induced in all 
experimental groups. 
To test whether the activation of AT2 receptors exerts stimulatory effects on the 
SM22 mRNA expression at earlier time points, cells were stimulated with Ang II ± 
losartan for 15, 30, 60 and 90 min. Fig 1-6 (B) shows that AT2 receptor activation 
already increased SM22 mRNA level after 15 min and the effect lasted up to 60 min.  
These results show that Ang II acting on its AT2 receptor up-regulates one of the 
VSMC-differentiation marker. Stimulation of AT1 receptors has no effect on the 
expression of this differentiation marker but reversed the AT2 receptor-mediated 
effect of the peptide.  
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Fig 1-6. (A) and (B). See following page for the legend. 
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1-6. Differential expression of SM22 in SK-UT-1 cells after treatment with 
Ang II. Quiescent SK-UT-1 cells were treated with Ang II (10-7 M) ± losartan (10-5 M) 
or PD123177 (10-6 M) for indicated time intervals in the presence of 1% ITS. Vehicle-
treated cells served as a control. Total RNA was isolated from the cells and 5 µg of 
total RNA were used for RT-PCR. Fifteen µl of PCR products were loaded on 1.1% 
agarose gel and run at 90 V for 90 min. (A) SK-UT-1 cells were treated with Ang II in 
the presence or absence of losartan or PD123177 for 1, 3 and 6 hrs. (B) SK-UT-1 
cell were treated with Ang II in the presence or absence of the AT1 receptor 
antagonist, losartan, for 15, 30 60 and 90 min. 
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Ang II and the expression of calponin in SK-UT-1 cells  
 
Calponin is another smooth muscle differentiation marker which is additionally 
involved in the SMC contraction. To further investigate the role of Ang II in the 
differentiation in SMC, the effect of the peptide on the expression of calponin mRNA 
was studied. The protocol was identical to the protocol applied when the effects of 
Ang II on the SM22 mRNA expression were investigated. Fig1-7 shows that 
incubation of cells with Ang II for 1 hr considerably increased mRNA levels of 
calponin only when the AT1 receptor was inhibited, no effect was detectable 
following incubation with the peptide alone for 3 or 6 hrs. Again, the effect of Ang II 
was AT2 receptor-mediated since PD123177 completely abolished the effect of Ang 
II on the mRNA expression of calponin. These results indicate that activation of the 
AT2 receptor up-regulates the transcription of calponin. Fig 1-8 summarizes the data 
from two independent experiments demonstrate that calponin wass up-regulated by 
Ang II only when the AT1 receptor was blocked by losartan. However, the effect can 
be detected only after peptide stimulation for 1 hr.  
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Fig 1-7. Differential expression of calponin in SK-UT-1 cells after treatment with 
Ang II. Quiescent SK-UT-1 cells were treated with Ang II (10-7 M) ± losartan (10-5 M) 
or PD123177 (10-6 M) for indicated time intervals in the presence of 1% ITS. Vehicle- 
treated cells served as a control. Total RNA was isolated from the cells and 5 µg of 
total RNA were used for RT-PCR. Fifteen µl of PCR products were loaded on 1.1% 
agarose gel and run at 90 V for 90 min. SK-UT-1 cells were treated with Ang II in the 
presence or absence of its receptor antagonists for 1, 3 and 6 hrs. 
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Fig 1-8. (A) and (B). See following page for the legend 
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(C) 
 
 
 
 
Fig 1-8. The densitometric quantification of agarose gel image for PCR 
products (calponin/beta-actin). Quiescent SK-UT-1 cells were treated with Ang II 
(10-7 M), Ang II (10-7 M) + losartan (10-5 M) and Ang II (10-7 M) + PD123177 (10-6 M), 
in the presence of 1% ITS. Total RNA was isolated at 1, 3 and 6 hrs post-treatment. 
Vehicle- treated cells were used as control. Results obtained in two independent 
experiments were pooled. Values represent means of n=2. 
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Effect of Ang II on calponin protein expression  
 
In the previous studies, it was demonstrated that Ang II, upon activation of AT2 
receptors, stimulates the expression of calponin mRNA. In this part, we investigated 
the effects Ang II on the calponin expression at the translation level, i.e. we quantified 
protein levels of calponin after stimulation with Ang II. The cells were cultured in the 
normal medium until 70% confluence and then the cells were serum deprived for 48 
hrs to obtain quiescence. The cells were then treated with Ang II (10-7 M) in the 
presence or absence of angiotensin receptor antagonists, losartan (10-5 M) and 
PD123177 (10-6 M), respectively, for 3, 6, 9, 12, 24 hrs in 1% ITS culture medium. 
The crude proteins were harvested with cell lysis buffer and 30 µg of total proteins 
was loaded on 10% polyacrylamide gel. Western blotting was carried out with human 
antibody against calponin (dilution 1:2500) followed by mouse peroxidase-linked anti-
human antibody (dilution 1:2000). Fig 1-9 shows that Ang II increased the calponin 
protein level at only one time point (9 hrs) and only when the AT1 receptor was 
inhibited by losartan. The effect was not detectable at earlier or later time points.  
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Fig 1-9. Effect of Ang II on calponin protein expression. Quiescent SK-UT-1 cells 
were treated with Ang II (10-7 M) ± losartan (10-5 M) and/or PD123177 (10-6 M) in the 
presence of 1% ITS for 3, 6, 9, 12 and 24 hrs. Vehicle-treated cells were negative 
controls and human umbilical smooth muscle cells served as positive controls. Crude 
proteins were harvested in cell lysis buffer containing 50 mM Tris-HCl (pH 8.0), 0.25 
M NaCl; 0.5% NP-40; 1 mM PMSF; 1 µg/ml aprotinin; 1 µg/ml leupeptin; 20 µg/ml 
TPCK. 30 µg of total proteins were loaded on 10% SDS polyacrylamide gel and run 
at 150 V for 65 min. Proteins were then transferred on PVDF membrane and 
incubated with the first antibody followed by incubation with horseradish peroxidase-
labelled second antibody. Three to 5 independent experiments were carried out.  
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Ang II and apoptosis-induction in SK-UT-1 cells evaluated by TUNEL method  
 
Recent findings indicate that Ang II acting on the AT2 receptor not only promotes cell 
differentiation, but can also induce apoptotis. In the following part, it was studied 
whether SK-UT-1 cells increasingly undergo apoptosis when they are exposed to 
Ang II. TUNEL and DNA-ladder methods were used.  
In the TUNEL experiment, SK-UT-1 cells (5000/well) grew in 24 well-plates in normal 
medium for 72 hrs and then they were serum deprived for 48 hrs to obtain 
quiescence. These cells were then treated with Ang II (10-7 M) in the presence or 
absence of losartan (10-5 M) in 1% ITS medium for 24, 48, and 72 hrs to obtain the 
optimal time point for the experiment. Every 12 hrs, fresh Ang II and losartan were 
added to the culture medium. The rate of apoptotic events in the cells was 
investigated by the TUNEL method 24, 48 and 72 hrs after the onset of treatment of 
cells with Ang II or Ang II + losartan. In the second experiment, cells were treated 
with Ang II alone, or with Ang II combined with losartan or PD123177 (10-6 M) for 48 
hrs. Cells incubated with DNase served as a positive control whereas cells untreated 
with labeling enzyme for the first antibody served as a negative control (see Materials 
and Methods). Another control group represented cells treated with vehicle. Fig 1-10 
shows that apoptotic cells could be detected after treatment with Ang II plus losartan. 
Apoptosis was most pronounced after 48 hrs of stimulation with Ang II + losartan and 
diminished after 72 hrs of treatment. The results presented in Fig 1-10 and Fig 1-11 
show that Ang II induced apoptosis in SK-UT-1 cells when AT1 receptors were 
blocked, while in the presence of the AT2 receptor antagonist, no apoptosis was 
detectable. These data clearly indicate that the Ang II effect on apoptosis is AT2 
receptor-mediated.  
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Fig 1-10 . See page 70 for legend. 
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Fig 1-10. See page 70 for legend. 
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Fig 1-10. See page 70 for legend 
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Fig 1-10. Time-dependent induction of apoptosis post treatment with Ang II in 
SK-UT-1 cells Quiescent SK-UT-1 were treated with Ang II (10-7 M) ± losartan (10-5 
M) for 24, 48 and 72 hrs. Treated cells were subjected to TUNEL staining. DNase 
treated cells serves as a positive control. Nucleotides of stained with DAB-substrate 
were identified as apoptotic cells.  
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Ang II + los 72 hrs 
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Fig 1-11. See following page for legend. 
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Fig 1-11. Ang II induced apoptosis in SK-UT-1 cells was AT2 receptor-mediated. 
Quiescent SK-UT-1 cells were treated with Ang II (10-7 M) ± losartan (10-5 M) or 
PD123177 (10-6 M) per 12 hrs till 48 hrs. Cells were fixed with 4% paraformaldehyde 
(pH 7.4) and subjected to TUNEL staining. Cells treated with DNase were used as a 
positive control and untreated as a negative control. Three independent experiments 
were carried out. 
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Ang II and apoptosis-induction in SK-UT-1 cells evaluated by DNA-ladder 
method 
 
The protocol was identical to the previous TUNEL protocol. To obtain the optimal 
time point for the experiment, quiescent cells were treated with Ang II (10-7 M) in the 
presence or absence of losartan (10-5 M) in 1% ITS medium every 12 hrs. The cells 
were collected for DNA isolation at 24, 36, and 48 hrs after the onset of stimulation 
with the ligands. Treatment of quiescent SK-UT-1 cells with Ang II + losartan for 24, 
36 and 48 hrs induced fragmentation of DNA; the effect was most pronounced at 36 
hrs (Fig 2-11 A). In the second experiment, cells were treated with Ang II alone, or 
with Ang II combined with losartan or PD1123177. Cells treated with vehicle or with 
angiotensin receptor antagonists alone served as negative controls. The Ang II 
induced apoptosis in SK-UT-1 cells was most pronounced after 36 hr of peptide 
stimulation together with losartan. This effect was mediated by the AT2 receptor, 
since the fragmentation of DNA could be detected only when the AT1 receptor was 
blocked whereas no fragmentation of DNA was observed in the presence of the AT2 
receptor antagonist (Fig 1-12 B).  
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Fig 1-12 Ang II and apoptosis-induction in SK-UT-1 cells evaluated by the DNA-
ladder method. Quiescent SK-UT-1 cells were treated every 12 hrs with Ang II (10-7 
M) +/- losartan (10-5 M) and/or PD123177 (10-6 M) in the presence of 1% ITS. The 
cells were harvested after 24, 36 and 48 (A) or 36 (B) hrs of incubation with 
angiotensin receptor ligands. After DNA had been isolated (see Material and Method 
section), 3 µg of total DNA from each sample was loaded on 1% of agarose gel and 
run at 60 V for 3 hrs. Apoptotic cells provided in the "Apoptosis DNA-ladder Kit" 
served as positive control for the DNA isolation. Four independent experiments were 
carried out. Explanation of numbers in Fig.1-12: 1. DNA marker; Treatment with: 2. 
vehicle; 3. Ang II; 4. Ang II + losartan; 5. Ang II + PD123177; 6. Ang II + losartan + 
PD123177; 7. positive control. 
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Results ( section II ) 
 
AT2 receptor induced Zfhep expression in CEC 
 
Initial experiments carried out in our laboratory have demonstrated that Zfhep mRNA 
is increasingly expressed in PC12W cells when these cells are exposed to epidermal 
growth factor (EGF) (25ng/ml) ± Ang II (10-7 M). Zfhep was induced after 1 hr but 
down-regulated after 6 hrs of Ang II stimulation. Subsequent experiments have 
shown Ang II causes a rapid induction of Zfhep mRNA and this effect is abolished in 
the presence of the selective AT2 receptor antagonists, PD123177. These initial 
experiments indicated that Ang II may regulate the growth factor-induced Zfhep 
expression in PC12W cells, which express only the AT2 receptor. However, they 
have not answered the question whether Ang II via the AT2 receptor could directly 
regulate Zfhep in the absence of growth factor in cells of vascular origin.  
In the present experiments, the gene expression of Zfhep in rat CEC to study the 
AT2 receptor-related gene expression in cells of vascular origin in the presence or 
absence of growth factor basic fibroblast growth factor (bFGF) was investigated. In 
addition, these cells express both Ang II receptor subtypes which allowed to study 
the potential role of the AT1 and the AT2 receptors in Zfhep expression. The 
expression of both receptor subtypes in CEC was verified prior to the experiments by 
RT-PCR (Stoll et al., 1995). 
CEC were isolated from male Wistar rats. In the first set of experiments. The Ang II-
induced effects on Zfhep mRNA expression in the CEC over a time course of 1 to 6 
hrs were investigated. In quiescent CEC, 25 ng/ml bFGF stimulated Zfhep mRNA up 
to 10 fold (positive control ) (Fig2-1). Ang II (10-7 M), (3 hrs exposure) did not induce 
any Zfhep mRNA when both receptor subtype were accessible. However, after pre-
treatment with the selective AT1 receptor antagonist, losartan (10-5 M), stimulation 
with Ang II resulted in a marked Zfhep mRNA expression, an effect that even 
exceeded the effect induced by bFGF (27 fold). On the contrary, in the presence of 
the AT2 receptor antagonist, PD123177 (10-6 M), no Zfhep mRNA expression was 
detectable (Fig 2-1). 
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Fig 2-1. Differential expression of Zfhep mRNA in CEC exposed to Ang II +/- 
losartan or PD123177. Total RNA was isolated from quiescent CEC 3 hrs post 
stimulated with Ang II (10-7 M) +/- losartan (10-5 M) or PD123177 (10-6 M). An amount 
of 5 µg of total of RNA was used for RT-PCR. 15 µl of PCR product from each 
sample were loaded on 1.1% agarose gel and run at 90V for 90 min. CEC treated 
with 25 ng/ml bFGF used as positive control for Zfhep mRNA expression. 
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Effect of Ang II on Zfhep mRNA expression in CEC pre-stimulated with bFGF. 
 
Previous findings in our laboratory have demonstrated that Ang II significantly inhibits 
the proliferation of bFGF-stimulated CEC in a dose-dependent manner, and this 
effect can be prevented by PD 123177, whereas losartan was ineffective (Stoll et al., 
1995). In the present study it was attempted to investigate whether the previously 
described antiproliferative effect of the AT2 receptor in these cells was accompanied 
by changes in the expression of Zfhep mRNA under identical experimental 
conditions. The experimental protocols used in the previous and the present study 
were identical. Shortly after pretreatment CEC with bFGF for 16 hrs, the cells were 
exposed to Ang II (10-7 M) +/- losartan (10-5 M) or PD 1231777 (10-6 M) for 1, 3 and 6 
hrs. Fig 2-2 (A) shows representative data from RT-PCR in CEC. Fig 2-2(B) 
summarizes the data from 5-7 independent experiments. Compared to quiescent 
controls, Zfhep mRNA levels were no longer induced in these cells 16 hrs post-
stimulation with bFGF (Fig 2-2). Furthermore, Ang II alone did not markedly alter 
Zfhep mRNA expression in bFGF-treated cells, 1 and 3 hrs post-stimulation. 
However, in the presence of the AT1 receptor antagonist, losartan, a significant 
increase in Zfhep mRNA was observed up to 3 hrs post-stimulation with the peptide 
(p<0.01 vs bFGF + Ang II), an effect that was reversed by the addition of the AT2 
receptor antagonist PD123177 (p<0.01 vs bFGF + Ang II + PD123177 and p<0.05 vs 
bFGF + Ang II + losartan + PD123177). Stimulation of the AT1 receptor, did not 
affect Zfhep mRNA expression in the presence of bFGF (Fig 2-2). In addition, 
Northern Blot analysis was used to verify the AT2 receptor-mediated induction of 
Zfhep mRNA in CEC. Although the expression level of Zfhep was very low and the 
bands after Northern hybridization were week, an induction of Zfhep was observed 
after AT2 stimulation (bFGF + Ang II + losartan) supporting the RT-PCR data. The 
AT2 receptor-mediated induction of Zfhep was again an early (1 hr) and transient 
phenomenon. It is noticeable that the degrees of Zfhep expression in CEC treated 
only with bFGF and in non-treated quiescent cells were identical (Fig 2-3). 
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Fig 2.2 See the following page for the legend. 
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Fig 2-2. Effect of Ang II on the expression of Zfhep in CEC. Cells were pre-
stimulated (16 hrs) with bFGF (25 ng/ml). RNA was isolated 1, 3 and 6 hrs post 
stimulation with Ang II (10-7 M) +/- losartan (10-5 M) and/or PD123177 (10-6 M). A). 
representative gel images for Zfhep mRNA expression for 1, 3 and 6 hrs post-
stimulation.1: quiescent cells, 2: vehicle, 3: Ang II, 4: losartan + Ang II, 5: PD123177 
+ Ang II, 6: losartan + PD123177 + Ang II, 7: losartan, 8: PD123177, 9: losartan + 
PD123177, 10: H2O control. B). Graph showing the changes in expression based on 
densitometric analysis. 2-3 fold induction of Zfhep mRNA in the presence of Ang II + 
losartan at 1 and 3 hrs post-stimulation was detected (n=7 for 1 hr, n=5 for 3 hrs). ** 
time point 1 hr: p<0.01 vs Ang II, p<0,01 vs Ang II + PD123177 and p< 0.05 vs Ang II 
+ losartan + PD123177. * time point 3 hrs: p<0.05 vs Ang II, p<0.05 vs Ang II + 
PD123177, p<0.05 vs Ang II + losartan + PD123177. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2-3 Zfhep mRNA expression in CEC, Northern Blot analysis. The expression 
of Zfhep mRNA in CEC pre-stimulated with bFGF in response to Ang II (10-7 M) +/- 
losartan (10-5 M) or PD 1231777 (10-6 M) or losartan and PD 123177 alone, was 
investigated 1 hr after the stimulation with the angiotensin receptor ligands. Total 
RNA was isolated from the same samples as described above. 10 µg of total RNA 
from each sample were loaded on 1% of agarose gel for RNA isolation and run at 18 
mA in 1 X MOPS buffer for 17.5 hrs (see Material and Methods section). 28s RNA 
served as controls for equal loading of lanes. 
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Results (section III ) 
 
Ang II-induced differentiation in PC12W cells: Involvement of NO  
 
In homogenates from the aorta of SHR, Ang II increased cGMP levels after pre-
treatment with losartan to block the AT1 receptor, indicating that this effect is AT2 
receptor-mediated (Gohlke et al., 1998). Correspondingly, inhibition of the AT2 
receptor completely abolished the Ang II-induced cGMP production. However, 
blockade of the bradykinin B2 receptor by icatibant also inhibited this effect. These 
findings point to a link between AT2 receptors and NO production through B2 
receptor activation, since activation of B2 receptors increases NO production which, 
in turn, enhances the activity of soluble guanylate cyclase to produce cGMP (Gohlke 
et al., 1998). Ang II induces differentiation in PC12W cells, which exclusively express 
the AT2 receptor (Meffert et al., 1996). In the last part of the study, the possible 
contribution of the BK/NO cascade to the differentiation in PC12W cells induced by 
activation of AT2 receptors was invesigated. 
Quiescent PC12W cells, cultured in collagen A pre-treated dishes, were stimulated 
daily with NGF (positive control) or with Ang II (10-7 M) in the presence or absence of 
the NO synthase (NOS) inhibitor, L-NAME (10-5 M), for 6 days. The degree of cell 
differentiation was evaluated by counting of neurite outgrowths per 100 cells (see 
Materials and Methods). Only the numbers of medium length neurites are presented 
in this section. 
As expected, both, NGF and Ang II stimulated neurite outgrowth in quiescent PC12W 
cells (Fig. 3-1). The Ang II-induced differentiation in PC12W cells was quantitatively 
similar to that induced by NGF. In contrast to the previous report (Meffert et al., 1996), 
NGF (0.5 ng/ml) did not potentiate the Ang II-induced cell differentiation. NOS 
synthase inhibitor, L-NAME, completely blocked the effect on differentiation of 
PC12W cells induced by Ang II in the presence or absence of NGF (0.5 ng/ml) (Fig 
3-2). 
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Fig. 3-1. Morphological change in PC12W cells treated with various 
differentiation inducers. (a). vehicle treatment, (b). NGF (50ng/ml), (c). NGF (0.5 
ng/mi), (d). Ang II (10-7 M), (e). NGF (0.5 ng/ml) + Ang II (10-7 M), (f). NGF (0.5 ng/ml) 
+ Ang II (10-7 M) + L-NAME (10-5 M), (g). Ang II (10-7 M) + L-NAME (10-5 M), h). 
sodium nitroprusside (SNP, 10-7 M). 
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Fig 3-2 Effect of NO synthase inhibition on the Ang II-induced differentiation in 
PC12W cells. PC12W cells were planted on collagen A pre-treated dishes and 
serum deprived for 48 hrs to obtain quiescence. Ang II (10-7) +/- L-NAME (10-5), Ang 
II +/- NGF (0.5 ng/ml) or Ang II + NGF + L-NAME were daily added to the cells. 
Vehicle-treated cells served as a negative control and cells treated with NGF (50 
ng/ml, black column) served as a positive control. The data are representative of two 
independent experiments. Values represent means ± SEM of n=20. ** p< 0.01 vs 
vehicle 
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Effect of NO on the differentiation in PC12W cells 
 
Data from the previous set of experiments indicate that NO is involved in the Ang II-
induced differentiation in PC12W cells, as inhibition of NO synthase by L-NAME 
abolished the effect of the peptide. In the following experimental setting, PC12W cells 
were exposed to various concentrations of freshly prepared sodium nitroprusside 
(SNP), an exogenous NO-donor, for 6 days, to investigate whether NO itself can 
stimulate the neurite outgrowth in these cells.  
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Fig 3-3. Effect of NO on the differentiation in PC12W cells. Quiescent PC12W 
cells were treated for 6 days with various concentrations of SNP (a NO-donor). SNP 
was added daily to the starve medium containing 0.5% iFCS. Negative control: cells 
treated with vehicle. Positive control: cells treated with NGF (50 ng/ml). The 
presented data is representative of two independent experiments. Values represent 
means ± SEM of n=20. 
 
The results show that exogenous NO induces neurite outgrowth in PC12W cells in a 
dose-dependent manner. Staining with trypan blue of PC12W cells exposed to SNP, 
revealed that SNP treatment at used concentration did not exert any toxic effects 
(data not shown). 
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Effect of NO synthase inhibition on the AT2 receptor-induced differentiation in 
PC12W cells: reversal by NO-donor 
 
To further investigate the importance of NO in the AT2 receptor-induced 
differentiation, an identical protocol to that employed in the previous experimental 
setting was used. Outgrown neurites in PC12W cells stimulated with Ang II in the 
presence or absence of the NO-donor, sodium nitroprusside, when NO synthase was 
inhibited by L-NAME was quantified. To verify the reproducibility of the observed 
effects and to assure identical experimental conditions for all groups, which was 
necessary for an appropriate evaluation of the obtained results, treatment 
combinations already used in the last set of experiment were also included. 
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Fig 3-4. Effect of NO-donor on the differentiation in PC12W cells induced by 
Ang II after inhibition of NO synthase. Quiescent PC12W cells were daily 
stimulated with Ang II (10-7 M), Ang II + L-NAME (10-5 M), Ang II + NGF (0.5 ng/ml) + 
L-NAME and Ang II + NFG + L-NAME + SNP (10-7 M) for 6 days. Vehicle-treated 
cells represented the negative and cells treated with NGF (50 ng/ml) served as the 
positive control. The presented data are representative of two independent 
experiments. Values represent means ± SEM of n=20. ** p<0.01 vs vehicle. 
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These results confirme the previous findings indicating the important role of NO in the 
Ang II-induced differentiation of PC12W cells. Inhibition of NO synthase abolished 
the effect of Ang II on neurite outgrowth, an effect which was reversed by the addition 
of an exogenous NO-donor.  
 
cGMP and cell differentiation 
 
Ang II-induced differentiation in PC12W cells is mediated by NO. NO activates a 
soluble guanylate cyclase to produce cGMP. cGMP might be a downstream mediator 
which activates intracellular events responsible for the initiation of differentiation. To 
test the hypothesis that cGMP can promote the cell differentiation, quiescent PC12W 
cells were treated with 8-bromo cGMP, a cGMP analogue which penetrates through 
the cell membrane. Again, the outgrowth of neurites was quantified. 
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Fig 3-5. Effect of 8-bromo-cGMP on the differentiation in PC12W cells. 
Quiescent PC12W cells were daily treated with of Ang II (10-7 M) + /- NGF (0.5 
ng/ml), 8-Bromo-cGMP (10-4 M) for 6 days. Vehicle-treated cells served as a negative 
control; cells treated with NGF (50 ng/ml) served as a positive control. The presented 
data are representative of two independent experiments. Values represent means ± 
SEM of n=20. ** p<0.01 vs vehicle. 
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Fig 3-5 shows that the cGMP analogue, 8-bromo-cGMP, induced differentiation in 
PC12W cells, and that the neurite outgrowth-promoting effect of 8-bromo-cGMP at 
the concentration used was comparable to that of NGF or Ang II.  
 
Ang II-induced differentiation in PC12W cells: Involvement of bradykinin.  
 
Icatibant (HOE 140), the antagonist for the B2 receptor, has been shown to inhibit the 
AT2 receptor-mediated generation of cGMP in rat aorta homogenates (Gohlke et al., 
1998). These findings point to a link between the AT2 receptor-mediated generation 
of cGMP and the B2 receptor. To study whether the B2 receptor is involved in Ang II-
induced cell differentiation, PC12W cells were cultured with Ang II (10-7 M) in the 
presence or absence of icatibant (10-5 M) for 6 days and the outgrown neurites were 
quantified. 
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Fig 3-6. The effect of B2 receptor antagonist, icatibant on the Ang II-induced 
differentiation in PC12W cells. Quiescent PC12W cells were daily treated with Ang 
II (10-7 M) in the presence or absence of B2 receptor antagonist icatibant (10-5 M) for 
6 days. Negative control: vehicle treated cells; positive control: cells treated with NGF 
(50 ng/ml). The presented data are representative of two independent experiments. 
Values represent means ± SEM of n=20.** p<0.01 vs vehicle. 
 
Fig 3-6 demonstrates that the B2 receptor antagonist did not inhibit the effect of Ang 
II on neurite outgrowth in PC12W cells. Present data indicate that the B2 receptor 
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was not a part of cellular and/or molecular mechanisms initiating cell differentiation in 
response to the AT2 receptor activation in PC12W cells. 
 
Effect of Ang II on NO synthase mRNA level in PC12W cells 
 
Ang II acting on AT2 receptors increases NO generation in PC12W cells. In the 
present study it is reported that BK, which represents one of the most potent 
activators of NO production, does not contribute to the AT2 receptor-mediated 
differentiation in P12W cells. In the last sets of experiments, it has been investigated, 
whether Ang II can directly modify the expression of NO synthase(s) to increase the 
NO generation in PC12W cells. It was attempted to answer the question whether 
activation of AT2 receptors could affect the expression of NO synthase(s) mRNA 
levels in PC12W cells and which NO synthase isoform is regulated by the AT2 
receptor in these cells. mRNA levels of three different isoforms of NO synthase were 
examined using RT-PCR. Briefly, 2.5 X 104/ml PC12W cells were planted in 10 cm 
dishes pre-treated with collagen A and incubated in normal medium for 24 hrs. The 
normal medium was replaced by starved medium to obtain quiescent PC12W cells. 
These cells were then stimulated with Ang II (10-7 M) and total RNA was isolated with 
Trizol-regent 2, 4, 8, 10 and 12 hrs post stimulation with the peptide.  
Fig 3-7 shows that Ang II up-regulated mRNA levels of endothelial NOS (eNOS) 
time- and dose- dependently with respect to post-stimulation time periods. The 
highest expression of eNOS mRNA was detected after 8 hrs (Ang II 10-7 M) and no 
further increase was detected after 8 hrs at longer time points.  
Increased mRNA levels of neuronal NOS (nNOS) were observed in PC12W cells 
after treatment with Ang II (10-7 M), Although the nNOS mRNA level in PC12W cells 
was lower 8 hrs post-treatment with Ang II (10-7 M) compared to that of 2 hrs 
treatment, an exaggerated expression of the mRNA was detected 12 hrs post-
stimulation with the peptide.  
Surprisingly, inducible NOS (iNOS) mRNA could be reduced in PC12W cells after 2 
hrs incubation with Ang II (10-7 M), but up-regulated at higher dose of Ang II (10-5 M) 
8 hrs post stimulation with the peptide. 
Taken together, three isoforms of NO synthase(s) were found to be expressed in 
PC12W cells. The levels of RNA of both constitutive NOS, neuronal NOS and 
endothelial NOS, were up-regulated following treatment with Ang II. However the 
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RNA levels of inducible NOS were at first reduced following stimulation with Ang II. 
The combined effects of NOS isoforms on Ang II induced differentiation in PC12W 
cells are still unknown. 
 
 
 
(A) (B) 
 
     Ang II (10-7 M)         8 hrs post-stimulation 
 
 
 
 
 
 
Fig 3-7. Expression of NO synthase(s) mRNAs in PC12W cells after stimulation 
with Ang II. Quiescent cells were incubated with Ang II (10-7 M) and total RNA was 
isolated 2, 4, 6, 8, 10 and 12 hrs post stimulation with the peptide. RT-PCR was 
carried out with 5 µg of total RNA using specific eNOS, iNOS and nNOS primers in 
the PCR procedure. 10 µl of each PCR product were loaded on 1.2 % agarose and 
run at 70 V for 90 minute. Bands were visualised by 0.5 µg/ml of ethidium bromide. 
eNOS, iNOS and nNOS were identified by 384 bp, 581 bp or 534 bp bands 
respectively. (A) time- dependent regulation of NO synthase by Ang II (10–7 M) in 
PC12W cells. (B) dose- dependent regulation of NO synthase by Ang II (8 hrs after 
stimulation) in PC12W cells. 
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Evaluation of the angiotensin receptor subtypes in PC12W cells 
 
It has been reported that PC12W cells express only the AT2 receptor at the 
passages lower than 18. To further confirm that the data obtained above are AT2 
receptor-mediated, RT-PCR and binding assay were used to evaluate the 
angiotensin receptor subtype in PC12W cells. Cells were cultured in 10 cm dishes or 
24 well plates with normal mediun till confluence. Total RNA was isolated using Trizol 
reagent for the AT1 and AT2 receptor PCR. Fig 3-8 (A) shows that at the cell 
passages we used for the experiments there were only the AT2 receptor but not the 
AT1 receptor expression. Binding assay further confirmed the results (Fig.3-8). 
 
(A) 
 
 
 
 
 
Fig 3-8. See following page for accompanying legend. Number represents the cell 
passages. 
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Fig. 3-8. AT1 and AT2 receptor assay for PC12W cells. (A).Total RNA was 
isolated from PC12W cells in different passages. 5 µg of total RNA were used for RT-
PCR. 15 µl of PCR product were loaded on a 2.0% agrose gel and run at 70V for 90 
min. AT1 and AT2 receptors were identified by 122 bp or 154 bp bands respectively. 
(B). [125I]-Ang II binding activity in the presence of angiotensin receptor ligands on 
PC12W cells. Confluence PC12W cells were incubated with [125I]-Ang II (40 pM/well) 
in the presence of Ang II, or PD123319, or losartan (1 µM each) for 2 hrs, at 37°C. 
Data are shown of a single experiment. Dat points correspond to an average of n =4. 
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Discussion ( section I ) 
 
Expression of Ang II receptors in SK-UT-1 cells 
 
A number of studies have reported that Ang II via its AT1 receptors can initiate 
proliferation, hypertrophy or hyperplasia in various tissues. In contrast, stimulation of 
AT2 receptors leads to anti-proliferation and promotes differentiation and may, under 
certain conditions, initiate cellular mechanisms leading to apoptosis (Unger, 1999). 
Both subtypes of Ang II receptors are also present in smooth muscle cells (SMC) of 
the uterus. In non-pregnant uterus, the AT2 receptors predominate and their 
expression varies dramatically during the menstrual cycle and are down regulated 
during gestation. AT1 receptors are also expressed in the myometrium and their 
numbers do not change during the menstrual cycle or gestation (Mancina et al., 
1996).  
 
The fact that Ang II acts, on one side, as a growth hormone promoting hypertrophy 
and hyperplasia and, on the other side, initiates differentiation and /or apoptosis, 
indicates that the peptide and its receptors may also play a role in processes related 
to the tumorigenesis. For instance, the AT2 receptor mRNA levels have been 
reported to be dramatically decreased in adrenal adenomas of both, Cushing´s and 
Conn´ syndroms (Kitamura et al., 1998). 
 
SK-UT-1 cells represent a human uterus leiomyosarcoma cell line. No data were 
available whether SK-UT-1 cells express angiotensin receptors. Binding assays using 
whole cells from SK-UT-1 cells failed to reveal angiotensin binding sites. Similarly, no 
measurable amounts of mRNA for the AT2 receptor have been detected using PCR 
with standard condition, indicating that, if AT2 receptors are expressed in these cells, 
their number must be very low. Single cell PCR was successfully used in our 
laboratory to detect AT2 receptor mRNA in a single cardiomyocyte cells (Busche et 
al., 2000). Using this slightly modified method, we have been able to detect mRNAs 
for the AT2 receptor subtype. The mRNA levels were very low but clearly detectable 
indicating that these cells in fact express AT1 and AT2 receptors. The expression of 
the AT2 receptor was extremely low during the incubation with growth factors but 
considerably increased when the cells were serum deprived. Studies using other cell 
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lines or primary cells including myocytes isolated from neonatal rat heart, PC12W or 
R3T3 cells, have also reported that serum deprivation causes up-regulation of the 
AT2 receptor (Kijima et al., 1996; Li et al., 1998). The results from the present studies 
support the hypothesis that Ang II can contribute to the regulation of processes linked 
to tumorigenesis. When AT1 receptors are increasingly expressed, Ang II would 
exert growth-promoting actions and stimulate proliferation. On the contrary, activation 
of AT2 receptors would suppress growth and rather promote differentiation. 
Furthermore, the findings demonstrating the existence of the AT1 and the AT2 
receptor in human uterus leiomyosarcoma cells and the regulatory effects of growth 
factors on the expression of the AT2 receptor, indicate that these cells may represent 
a relevant model to investigate the role of the angiotensin receptors in tumorigenesis.  
 
Effect of Ang II on the proliferation of SK-UT-1 cells 
 
The 3H-thymidine incorporation test provides a suitable method to investigate the rate 
of DNA synthesis and enable to draw conclusions on cell proliferation. Increased 3H-
thymidin incorporation indicates enhanced mitogenic activity. 
 
In our experiments carried out in promoting or quiescent SK-UT-1 cells, Ang II had no 
effect either on the cell numbers or on the rate of DNA synthesis. Furthermore, 
neither inhibition of AT1 receptors nor inhibition of AT2 receptors had any effect on 
proliferation of SK-UT-1 cells. Additional experiments in confluent cells (high density 
of cells in the culture), with supposedly up-regulated cell surface AT2 receptors, have 
also demonstrated that Ang II does not influence proliferation of these cells, nor does 
it interfere with mitogenic effects induced by growth factors. These data suggest that 
growth factors seem to represent a very strong mitogenic stimulus for these cells 
which cannot be affected by angiotensin receptors. 
 
The failure of Ang II to reduce through activation of the AT2 receptor the 3H-
thymidine incorporation in SK-UT-1 cells is rather surprising. Growth inhibitory effects 
of Ang II have been convincingly demonstrated in PC12W, and R3T3 cells, which 
express exclusively AT2 receptors, or in CEC, when AT1 receptors were inhibited by 
AT1 receptor antagonists. In all these cell lines, inhibition of 3H-thymidine 
incorporation is observed when the cells are exposed to Ang II. One explanation for 
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the failure of Ang II to inhibit proliferation of SK-UT-1 cells via AT2 receptors might be 
the fact, that in SK-UT-1 cells, which represent a very malignant tumor cell line, the 
mitogenic effects of growth factors are extremely exaggerated and they cannot be 
offset by a concomitant activation of AT2 receptors. Moreover, the low expression of 
AT2 receptors must also be considered as the overnight exposure of cells to growth 
factors (10% iFCS or 1% ITS) might down-regulate the expression of the AT2 
receptors. We indeed observed that the expression of AT2 receptors was extremely 
low in proliferating compared to quiescent SK-UT-1 cells. Under these conditions the 
AT2 receptor-mediated anti-mitogenic effect could hardly be achieved. However, 
even at the absence of growth factors in the culture medium, the cell proliferation 
was not be influenced by the treatment with Ang II although higher AT2 receptor 
mRNA levels were detected. Rapid inactivation of Ang II or the antagonists in the 
medium can be excluded since these compounds retained full biological activity 
under similar culture condition in the experiment carried out in PC12W, R3T3 cells 
and CEC. In these experiments, Ang II acting on the AT2 receptor clearly attenuated 
proliferation and promoted differentiation. 
 
The reason why the stimulation of AT2 receptors in SK-UT-1 cells did not induce any 
proliferation-inhibitory effects is presently unknown. It could be due to the fact that 
the AT2 receptor may exert its growth-inhibiting actions on various levels including 
modulation of the signaling of other, most probably, growth factor receptors or the 
activity of transcription factors. It can be assumed that these rapid proliferating tumor 
cells lack of the target molecule(s) mediating the growth-arrest following activation of 
AT2 signaling pathways, or that these target molecules are not expressed in 
sufficient amounts to inhibit proliferation. 
 
Selective activation of AT1 receptors in SK-UT-1 cells unexpectedly failed to 
stimulate proliferation. Again, the link between the AT1 receptor signaling and down-
stream events promoting proliferation in cells with a rapid cell cycle may be absent or 
differ from those operating in other, slowly proliferating tumor cells, such as R3T3 
and PC12W cells. Further experiments using in SK-UT-1 cells or other established 
cell culture models expressing AT1 and AT2 receptors might help to explain the 
discrepancies between the above mentioned findings and the present results.  
  
 
94
 
Ang II and the expression of the differentiation markers, SM22 and calponin 
 
Activation of AT2 receptors in SK-UT-1 did not exert any growth-inhibitory actions. In 
further experiments, it was investigated whether activation of this angiotensin 
receptor subtype would induce differentiation. 
 
Generally, to study cell differentiation, an analysis of morphological changes and/or a 
detection of specific differentiation markers can be employed. Several specific 
differentiation markers have been reported to evaluate the differentiation in SMC, 
such as α-SM actin (Blank et al., 1992), smooth muscle myosin heavy chain (Madsen 
et al., 1997), β tropomyosins (Kashiwada et al., 1997), calponin (Gimona et al., 1992; 
Shanahan et al., 1993; Duband et al., 1993), SM22α (Solway et al., 1995), h-
caldesmon (Yano et al., 1995) and α1 integrin (Obata et al., 1997).  
 
This study demonstrates that Ang II considerably increased SM22 mRNA expression 
in the presence of the growth factor, ITS. This effect was mediated by the AT2 
receptor, since firstly, it could be detected only when the AT1 receptor was blocked 
by losartan and, secondly, pretreatment with the selective AT2 receptor antagonist 
completely blocked the Ang II induced up-regulation of SM22 mRNA. Interestingly, 
the up-regulation of SM22 mRNA level was detected at the early time point, 1 hour 
post Ang II treatment, and no more detectable 3 hours post Ang II treatment.  
 
SM22 is a 22-kDa SMC lineage-restricted protein associated with cytoskeletal actin 
filament bundles in contractile SMC thus representing an important differentiation 
marker for SMC (Duband et al., 1993; Lees-Miller et al., 1987). In VSMC, SM22 is 
expressed abundantly and exclusively during postnatal development. The expression 
of SM22 was also observed in cardiac and skeletal muscle cells, and it appears in 
the early embryogenesis about day E9 which suggests that the expression of the 
SM22 is associated with the early development of SMC.  
 
The early induction of SM22 mRNA expression by the AT2 receptor stimulation could 
be detected because the basal SM22 mRNA levels were low. A low expression of 
SM22 was associated with cellular events linked with the dedifferentiation of SMC 
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(Hayashi et al., 1998). The appearance of SM22 mRNA expression in SK-UT-1 cells 
may serve as a marker for the switch to cellular programs associated with 
differentiation. The up-regulation of SM22 mRNA levels by the AT2 receptor 
activation suggests that Ang II acting on the AT2 receptor can be considered as a 
factor promoting differentiation in uterus leiomyosarcoma cells by changing the 
phenotype of these tumor cells as a result of the cytoskeleton reorganization.  
 
Three and 6 hours lasting stimulation of SK-UT-1 cells with Ang II in the presence or 
absence of angiotensin receptor antagonists and under the same culture conditions, 
an up-regulation of SM22 mRNA levels was observed in all experimental groups. The 
up-regulation of SM22 expression in all experimental groups after 3 and 6 hours of 
incubation can be related to the action of ITS. It has been reported that insulin and 
insulin-like growth factors (IGF-I and IGF-II) markedly prolong the differentiated 
phenotype in primary SMC (Hayashi et al., 1998). Even though there is not any data 
indicating that insulin regulates the expression of SM22 in SMC, it can be concluded 
that insulin induced the up-regulation of SM22 mRNA observed at the later time 
points. It is assumed that, after 3 or 6 hours of stimulation of SK-UT-1 cells with 
medium containing 1% ITS (insulin), any induction of SM22 mRNA levels by AT2 
receptor activation was overridden by their up-regulation caused by insulin. 
 
It has been reported that the AT2 receptor mRNA expression in the mouse aorta is 
low during the early fetal development (E13-E15) but increases rapidly during later 
phases of the fetal development (E18-E21). In parallel with the increased AT2 
receptor occurrence, the mRNA expression of calponin in the aorta tissue is 
“switched on” at E13-E15 and continues to increase thereafter. Thus, the rate of 
calponin synthesis is closely associated with the AT2 receptor expression which 
suggests the calponin may be regulated by the AT2 receptor (Yamada et al., 1999). 
 
It has been well documented that calponin is expressed in differentiated SMC but in 
dedifferentiated cells, calponin expression is down regulated. The present results 
show that Ang II can up-regulate calponin in SK-UT-1 cells. A continuous exposure to 
the peptide for 1 and 3 hours caused an up-regulation of calponin mRNA when the 
AT1 receptor was blocked by losartan. The effect of Ang II was abolished after 6 
hours of incubation. Correspondingly, increased levels of calponin protein were 
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detected after 9 but not any more after 12 hours of incubation with Ang II plus 
losartan (see Fig 1-9). 
 
The expression of SMC differentiation genes seems to depend on the cell type and 
the cell phenotype. In differentiated leiomyomas cells, calponin expression cannot be 
further stimulated because the basal expression of calponin is relatively high, but it 
can be dramatically up-regulated in differentiated leiomyosarcoma cells in which the 
basal expression is low. These findings indicate that the regulation of calponin rather 
occurs in malignant tumor cells compared to benign tumor cells. Correspondingly, the 
AT2 receptor-mediated up-regulation of calponin expression was observed in the 
leiomyosarcoma cells with rapid cell cycle growth. AT2 receptors have been reported 
to be decreased in cells incubated with growth factors. Indeed, a very low expression 
of AT2 receptor mRNA levels in SK-UT-1 cells cultured 48 hours with ITS was 
observed (Fig 1-1). When Ang II and losartan were added to SK-UT-1 cells together 
with ITS, the peptide stimulated calponin expression up to 3 hours of the stimulation 
since AT2 receptors were still present. The failure of Ang II to stimulate calponin 
expression 6 hours after the onset of the incubation with the peptide was most 
probably due to a reduction of AT2 receptors induced by ITS.  
 
Only few investigators have investigated the effect of the AT2 receptor on calponin 
gene regulation. The conclusions are rather equivocal. Dulin and co-workers (2001) 
reported that Ang II increased calponin levels in rat aorta SMC is in dose- and time-
dependent manner. This Ang II effect was AT1 receptor-mediated since the AT1 
receptor antagonist, losartan, abolished it, while the AT2 receptor antagonist, 
PD123319, was without effect. The authors used primary-derived aortic SMC from 
adult  Wistar-Kyoto rats between passage 5 and 15. The cells were treated with Ang 
II in serum-starved medium, and the authors did not report on the numbers of AT1 
and AT2 receptors in their cell preparation. Similar conclusions have been drawn 
from experiments carried out rat aortic SMC in vitro (di Gioia et al., 2000) and in vivo 
(Castoldi et al., 2001). Furthermore, Ang II was reported to down-regulate the level of 
calponin in primary SMC isolated from the gizzard of 15-day old chick embryos while 
insulin had an opposite effect (Hayashi et al., 1998). Compared to Ang II, serum, 
EGF, TGFβs and PDGFs reduced the calponin mRNA expression to a negligible 
level and produced a marked de-differentiation. Again, the authors did not report on 
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the expression of AT1 and AT2 receptors. Taken together, it appears that both Ang II 
receptors contribute to the regulation of calponin expression and differentiation 
processes in SMC depending on the origin and type of the cells and experimental 
conditions. 
 
PC12W cells treated with Ang II increasingly express biochemical differentiation 
markers and exhibit typical morphological changes, such as neurite outgrowth, which 
also represents a typical differentiation marker. It was expected that the up-regulation 
of two differentiation markers, SM22 and calponin, by Ang II in SK-UT-1 cells would 
also be associated with morphological changes of these cells. In fact, the cultured 
cells grew in an irregular fashion similar to the untreated controls. This may be due to 
the fact that the AT2 receptor-mediated up-regulation of differentiation markers in 
SK-UT-1 cells was investigated in proliferating cells while the Ang II-induced 
differentiation in PC12W cells was carried out in quiescent cells. As already 
mentioned above, calponin levels are also dramatically up-regulated in serum 
deprived quiescent SK-UT-1 cells. These non-proliferating cells with such a high 
calponin level do not respond with additional expression of calponin to compounds 
inducing differentiation. However, when these quiescent cells are exposed to ITS, a 
growth factor, Ang II still induces biochemical differentiation markers, but any 
attempts to induce morphological changes typical for the differentiation are obviously 
overridden by the further proliferation-promoting effects of ITS.  
 
Effect of Ang II on the apoptosis of uterus leiomyosarcoma cells 
 
Apoptosis plays a major role during development, homeostasis and immune 
response in multicellular organisms. It has been reported that Ang II induces 
apoptosis in many tissues and cell lines through AT2 receptor activation, for instance 
in PC12W cells (Gallinat et al., 1999; Yamada et al., 1996), fibroblasts (Li et al., 
1998), R3T3 cells (Yamada et al., 1996), VSMC (Nagashima et al., 2001), 
cardiomyocyte (Goldenberg et al., 2001) and endothelial cells (Hamet & deBlois, 
2001). The dramatic increase in calponin mRNA level in serum deprived SK-UT-1 
cells and the present observation of an AT2 receptor-mediated up-regulation of 
calponin mRNA and protein levels raised the speculation that the AT2 receptor 
activation in these cells may induce apoptosis. Indeed, Ang II caused apoptosis in 
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SK-UT-1 cells after 36 or 48 hours of peptide treatment. This effect was AT2 
receptor-mediated since it was observed only when AT1 receptors were blocked. 
PD123177 treatment abolished the apoptosis-promoting effect of Ang II in these 
cells. The reason why Ang II induced apoptosis in SK-UT-1 only at time points 36 or 
48 hours is at the present unknown. 
 
Low expression of AT2 receptors in these cells treated with culture medium 
containing 1% ITS might be responsible for the delayed apoptotic effect of Ang II. 
Following serum deprivation, the cells became quiescent and the number of AT2 
receptors was relatively high. Then the cells were incubated with medium containing 
ITS which, on one side, promotes proliferation and on the other side down-regulates 
the AT2 receptor expression. During the first 6 - 9 hours, when the number of AT2 
receptors was still high, Ang II enhanced the expression of differentiation markers. 
This differentiation-promoting action of Ang II was directly opposed to the 
proliferation-promoting action of ITS. At later time points, ITS suppressed the 
expression of AT2 receptors, their numbers were steadily decreasing and Ang II was 
not able to induce differentiation markers. Since proliferation is preferred in SK-UT-1 
cells incubated with a growth factor, Ang II acting on AT2 receptors promoted 
apoptosis only in a small population of these cells. Ang II acting on AT2 receptors 
can promote both, tumor cell differentiation and apoptosis, depending on a number of 
factors such as the presence of growth hormones, number of membrane AT2 
receptors and the ratio of AT1/AT2 receptors. The tendency for malignant cells to 
undergo apoptosis is directly related to tumor cell differentiation (Saegusa et al., 
1995), and it cannot be excluded that the up-regulated calponin is one of the 
predictors of apoptosis since enhanced expression of this protein preceded the 
induction of apoptosis in SK-UT-1 cells.  
 
Discussion ( section II ) 
 
Effect of Ang II on the Zfhep expression in CEC 
 
As already mentioned, the control of cellular proliferation, differentiation and 
apoptosis appears to belong to the major actions of Ang II. Growth stimulatory effects 
induced by Ang II are usually associated with the stimulation of AT1 receptors (Aceto 
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& Baker, 1990; Paquet et al., 1990), while AT2 receptors have been shown to inhibit 
the proliferation of various cell types in vitro (Meffert et al., 1996; Stoll et al., 1995; 
Tsuzuki et al., 1996) and in vivo (Munzenmaier & Greene, 1996; Nakajima et al., 
1995). While the signaling cascade of the AT1 receptor is well characterized, the 
signaling of the AT2 receptor remains still a mater of controversy. A hallmark of AT2 
signaling appears to be the activation of phosphatases which inhibit the 
phosphorylation steps in growth-promoting signaling. Even less is known about target 
genes of the AT2 signaling cascade. To further characterize downstream events of 
AT2 signaling and the AT2-induced antigrowth actions, differentially expressed genes 
following stimulation of AT2 receptors in PC12W cells was identified using differential 
mRNA display. Zfhep is one of the three genes which were successfully confirmed by 
Northern Blot and which seem to be directly related to the proposed function of the 
AT2 receptor. Zfhep belongs to the Zfhep family of Drosophila genes that are 
required for differentiation of the CNS and in the regulation of cell fate (Lai et al., 
1991; Lai et al., 1993). The AT2 receptor is known to induce differentiation of PC12W 
cells (Meffert et al., 1996). Previous findings have demonstrated that in quiescent 
PC12W cells Ang II transiently induced the expression of Zfhep, one and three hours 
following stimulation, an effect that was AT2-specific since it was abolished by the 
AT2 antagonist, PD123177. The present study was designed to determine whether 
the observed induction of Zfhep mRNA was specific to cells of neuronal origin, which 
undergo differentiation, or whether Zfhep mRNA induction can also be observed in 
cells of vascular origin; i.e., CEC. This might be of a particular interest because, while 
PC12W cells express only AT2 receptors, CEC express both angiotensin receptor 
subtypes. Correspondingly, these cells respond differently to Ang II depending on 
which receptor subtype predominate. 
 
The present results clearly demonstrate that the AT2 receptor also induced Zfhep in 
CEC. However, the effect of Ang II in CEC was only detectable when AT1 receptors 
were blocked by losartan. The finding, that simultaneous stimulation of both 
receptors by Ang II was ineffective on Zfhep expression suggests that the AT1 
receptor does not stimulate Zfhep transcription but down-regulates the AT2- 
receptor-induced Zfhep mRNA expression. This is an interesting finding, because in 
all previous studies, the Ang II- mediated induction of transcription factors was 
attributed to the AT1 receptor, and this effect was unopposed by the AT2 receptor. 
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This is the first report which describes activation of a transcription factor via AT2 
receptor activation which is opposed by the AT1 receptor. Furthermore, the results 
presented also show that the induction of Zfhep mRNA is not specific to cells of 
neuronal origin which undergo differentiation, but can also be observed in cells of 
vascular origin. In addition, Zfhep not only represents a suitable marker for AT2 
receptor activation but may also link AT2 signaling and downstream events involved 
in the proposed function of the AT2 receptor in processes occurring during 
development and regeneration. 
 
From these results, it is apparent that Zfhep can represent a suitable marker for the 
study of the AT2 receptor activation and subsequent elucidation of signaling events 
involved in the regulation of cell growth and differentiation. For example, a yeast-2-
hybrid screen revealed an interaction between the third intracellular loop of the AT2 
receptor and a member of the EGF receptor family, ErB3, as a part of a novel 
signaling mechanism for the AT2 receptor mediated inhibition of cell growth (Knowle 
et al., 2000). Our initial experiments for the differential mRNA display examined the 
influence of the AT2 receptor activation upon EGF-induced growth in PC12W cells 
and led to the discovery of Zfhep. Therefore, Zfhep may represent an important link 
between early events in receptor-receptor cross talk, such as AT2-ErbB3, and 
downstream target genes involved in cellular growth and differentiation. The 
presence of a homoeobox domain implies Zfhep in putative actions on differential 
genes. The mouse homologue gene, ZEB, was shown to down-regulate the activity 
of a number of transcription factors involved in cell differentiation, such as c-myb, NF-
κB p65, ITF-1 and myoD (Postigo & Dean, 2000). Since differentiation processes 
require positive as well as negative regulation of transcription factors to ensure a 
proper temporo-spatial pattern of gene expression, it has been postulated that ZEB is 
involved in the orchestration of differentiation events. Similarly, the AT2 receptor has 
been proposed to be involved in events associated with differentiation. It is 
conceivable that via the induction of Zfhep, the AT2 receptor can exert its role in the 
orchestration of differentiation during embryogenesis.  
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Discussion (section III ) 
 
Ang II-induced differentiation in PC12W cells: The role of the AT2 receptor 
 
In the last part of this study, the signaling pathways associated with the AT2 receptor 
activation in PC12W cells, which express almost exclusively the AT2 receptor at low 
cell passages (< 18), were investigated. Results obtained previously in our laboratory 
have shown that Ang II induces neurite outgrowth in these cells. The outgrowth of 
neurites represents a fundamental morphological process associated with neuronal 
differentiation, development and remodeling in neuronal tissue. The present findings 
demonstrate that generation of nitric oxide resulting in an increased formation of 
cGMP constitutes, at least in part, the mechanism, by which Ang II promotes the 
differentiation of  PC12 W cells. The present results also indicate that Ang II, via the 
AT2 receptor, time- dependently up-regulates the transcription of eNOS and nNOS. 
 
Both, axons and dendrites sprouting from cells in vitro are named neurites, and are 
fundamental morphological characteristics for neuronal differentiation. In the present 
experiments, neurite sprouting was used as a marker to investigate the role of 
bradykinin and NO in the Ang II-induced differentiation of PC12W cells.  
 
The expression of mRNAs coding for the angiotensin receptors was examined by RT-
PCR at different cell passages. At cell passages less than 17, AT1 receptor mRNA 
was not detected. Angiotensin receptor binding assays also confirmed that PC12W 
cells used for the present studies expressed only the AT2 receptor.  
 
Several studies have demonstrated that the differentiation of NG108-15 cells initiated 
by addition of cAMP, DMSO or by serum deprivation selectively increased AT2 
receptor expression, but there was no obvious correlation between the extent of AT2 
receptor expression and the differentiation process (Laflamme et al., 1996; Seidman 
et al., 1996). In the present study, it was also found that the expression of the AT2 
receptor was increased after serum deprivation but not affected after incubation with 
Ang II or NGF for 6 days (data not shown). In line with previous findings, AT2 
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receptor mRNA levels did not correlate with morphological changes related to 
differentiation. 
 
PC12W cells stimulated with NGF and NG108-15 cells treated with cAMP analogues 
are two models frequently used to study neuronal differentiation (Laflamme et al., 
1996; Tojima et al., 2000). Recent studies have demonstrated that Ang II by 
activating the AT2 receptor promotes differentiation in both neuronal cell lines as well 
as in microexplant cultures of rat cerebellum (Cote et al., 1999; Laflamme et al., 
1996; Meffert et al., 1996). The signal transduction mechanisms of these AT2 
receptor-mediated effects are still a matter of controversy. An NO-induced neuronal 
differentiation was firstly described in PC12 cells in which NGF increased NOS 
expression (Peunova & Enikolopov, 1995). Recently, NO has been reported to act as 
a second messenger directly involved in the action of Ang II on neuronal 
differentiation in NG108-15 cells (Cote et al., 1998). Although both, NGF and Ang II 
can increase NO production, the downstream signaling events activated by each of 
these compound are quite different. In NG108-15 cells, the AT2 receptor- mediated 
neurite outgrowth was accompanied by a decrease in P21ras activity and by a delayed 
increase in the activity of mitogen-activated protein kinases (MAPK), ERK1 (p44mapk) 
and ERK2 (p42mapk) (Gendron et al., 1999). On the other hand, in PC12W cells 
stimulated with NGF, induction of neurite outgrowth was initiated by an increase in 
P21ras activity and by a rapid and sustained increase in p42/p44mapk activity (Cowley 
et al., 1994; Pang et al., 1995). It appears, that in both models, the increase in 
p42/p44mapk activity is a prerequisite for the neurite outgrowth induced by the AT2 
receptor (Gendron et al., 1999; Stroth et al., 2000). In quiescent N1E-115 
neuroblastoma cells expressing only the AT2 receptor, basal MAPK activity was not 
affected by Ang II treatment. However, Ang II prevented the fetal-calf serum as well 
as epidermal growth factor- induced activation of ERK1 and ERK2 (Bedecs et al., 
1997). The Ang II-induced neurite outgrowth is also associated with alterations in the 
levels of microtubule-associated proteins (MAP). Ang II induces up-regulation of 
MAP2c in NG108-15 cells and MAP2 in PC12W cells, but down-regulates MAP1B in 
the latter (Laflamme et al., 1996, Stroth et al., 1998). Taken together, these studies 
point to a specific role of the AT2 receptor in neuronal cell differentiation and nerve 
regeneration via a cytoskeleton reorganization.  
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The effect of NO and cGMP on the AT2 receptor-mediated differentiation in 
neuronal cells 
 
NO appears to represent the link between AT2 receptor stimulation and changes in 
MAPK´s or MAP´s associated with differentiation. In the present study, evidence is 
provided that NO is a mediator of the Ang II-induced cell differentiation in PC12W 
cells. Firstly, blockade of NO synthase by L-NAME blunted the effect of Ang II on 
differentiation in these cells. Secondly, application of sodium nitroprusside, an 
exogenous NO-donor, mimicked the morphological changes observed in PC12W 
cells after AT2 receptor activation. In accordance with these findings, the 
morphological differentiation of NG108-15 cells induced by Ang II was also mediated 
by NO (Cote et al., 1998). NO was also reported to represent a crucial factor in the 
mechanisms responsible for the NGF-induced neuronal differentiation of PC12W 
cells (Peunova & Enikolopov, 1995). In the latter study, NGF was shown to activate 
NO synthase resulting in increased generation of NO. NO seems to be an important 
factor mediating the switch to cytostasis at the beginning of the differentiation events. 
 
Cellular actions of NO can be mediated directly; e.g., by protein nitrosylation or by 
activation of soluble guanylate cyclase to produce cGMP. The present data suggest 
that the effects of NO are mediated by cGMP. Daily application of the cGMP agonist, 
8-brom-cyclic GMP, was as efficient as Ang II in inducing the neurite outgrowth, 
indicating that activation of soluble guanylate cyclase by NO to increase the 
generation of cGMP most probably mediates the AT2 receptor-induced differentiation 
in PC12W cells. These observations are in line with those of Gendron et al (2002) 
who have reported that activation of the AT2 receptor in NG108-15 cells increases 
cGMP levels. We have also noticed, that  Ang II dose-dependently stimulated the 
production of cGMP in PC12W cells. The Ang II-induced cGMP formation was rapid 
and transient and could be abolished by co-incubation with the AT2 receptor 
antagonist, PD123319. Similar to these findings, enhanced cGMP formation was also 
observed in neuroblastoma neuro-2A cells following Ang II treatment. The proposed 
mechanisms involve activation of the soluble guanylate cyclase by NO (Chaki & 
Inagami, 1993). Taken together,  these results strongly suggest that the NO/cGMP 
pathway is involved in the AT2 receptor-mediated differentiation in neuronal cells. 
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However, several other, hitherto unknown factors and mechanisms may also play a 
role in the processes associated with the differentiation of cells of neuronal origin, 
especially, when Ang II or the AT2 receptor are not involved. Thus, Hindley et al 
(1997) also reported that NO enhanced the NGF-induced neurite outgrowth in PC12 
cells by a cGMP dependent pathway, but in the absence of NGF, NO failed to elicit 
neurite outgrowth. Similar findings were reported by Phung et al (1999) who showed 
that sodium nitroprusside alone did not stimulate the outgrowth of neurites in PC12 
cells. Furthermore, the differentiation-promoting effects of NO in the presence of 
NGF were independent of the guanylate cyclase/cGMP pathway (Phung et al, 1999).  
 
Bradykinin and the differentiation induced by Ang II in PC12W cells 
 
Our group has demonstrated in SHRSP that a rise in plasma Ang II concentration 
stimulated aortic cGMP generation by an AT2 receptor dependent mechanism. This 
effect of Ang II was abolished by blockade of the bradykinin B2 receptor as well as by 
NO-synthase inhibition suggesting that the Ang II-induced NO generation was 
mediated by bradykinin (Golhke et al., 1998). In the present study Ang II as well as 
bradykinin increased cGMP in PC12W cells. As expected, the enhanced cGMP 
production after treatment the cells with bradykinin could be completely abolished by 
the B2 receptor antagonist, icatibant. On the other hand, the Ang II-induced increase 
of cGMP levels was not reduced by icatibant, indicating that the generation of NO in 
response to Ang II in PC12 W cells was not mediated by bradykinin. In contrast to 
these findings, in bovine aortic endothelial cells, Ang II concentration-dependently 
increased both, the production of kinins as well as of cGMP (Korth et al., 1995; 
Wiemer et al., 1993,). The mechanism may involve activation of kininogenases by an 
AT2 receptor which would result in intracellular acidification and subsequent 
generation of bradykinin, as proposed in a recent study carried out in VSMC over-
expressing the AT2 receptor (Tsutsumi et al., 1999). In all these studies, the effect of 
Ang II on cGMP production was completely abolished by bradykinin B2 receptor 
blockade indicating that bradykinin represents a crucial factor for the Ang II-induced 
NO production in VSMC or endothelial cells. These findings demonstrate that the 
cellular mechanisms promoting NO production in response to Ang II differ between 
cells of neuronal origin, such as the PC12 W cells, and endothelial or VSMC.  
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In the present experiments, B2 receptor blockade did not significantly block the 
effects of Ang II on the differentiation of PC12W cells. These results clearly 
demonstrate that the Ang II-induced NO generation in PC12W cells does not require 
the generation of bradykinin and rather results from a direct activation of NOS. 
Indeed, Ang II, via activation of AT2 receptors, time- and dose-dependently up-
regulated the expression of eNOS in PC12W cells, but simultaneously reduced the 
expression of iNOS. The underlying mechanisms are not clear and further 
experiments are required to explain these findings. 
 
In conclusion, the presented data strongly supports previous findings demonstrating 
that Ang II induces differentiation in PC12W cells by activation of AT2 receptors. The 
data also indicate that NO and cGMP, but not bradykinin, mediate the AT2 receptor 
induced neurite outgrowth, which is intimately associated with the regeneration and 
remodeling of neuronal tissue.  
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Summary 
 
The major actions of Ang II, the main effector peptide of the renin-angiotensin 
system, are mediated by two G-protein coupled angiotensin receptor subtypes, the 
AT1 and the AT2 receptor. Most of the classical actions of Ang II in fluid and blood 
pressure homeostasis are mediated by the AT1 receptor, however, this receptor type 
may also initiate proliferation, hypertrophy and growth in various tissues. The AT2 
receptor is expressed at high density during fetal development and is less abundant 
in adult tissues. Ang II via the AT2 receptor may act as modulator of biological 
programs involved in embryonic development, tissue regeneration and protection, 
differentiation and in the initiation of processes leading to programmed cell death. 
There is substantial evidence that the AT2 receptor can offset or counteract the 
effects mediated by the AT1 receptor on cell proliferation.  
 
There is evidence indicating that Ang II interferes with a number of cellular processes 
in tumor cells. A useful tool in studying the role of angiotensin receptors in tumor 
tissue are leiomyosarcoma SK-UT-1 cells which express both angiotensin receptor 
subtypes. Experimental results obtained in these cells might be representative of AT1 
and AT2 receptor functions in tumor cells. To explore the role of AT1 and AT2 
receptors for the proliferation and growth of the human leiomyosarcoma, The 
expression of angiotensin receptors in leiomyosarcoma cell line SK-UT-1 and the 
effects of Ang II on the proliferation, differentiation and apoptosis in this cells line 
were studied. RT-PCR analysis revealed that SK-UT-1 cells express both subtypes of 
angiotensin receptors. Activation of neither receptor subtype did alter 3H-thymidine 
incorporation and the number of cells. However, stimulation of AT2 receptors up-
regulated mRNA levels of smooth muscle cell differentiation markers, SM22 and 
calponin. An effect which was, however, not associated with morphological changes 
of these cells. This was due to the fact that the AT2 receptor-mediated up-regulation 
of differentiation markers in SK-UT-1 cells was investigated in cells cultured in the 
presence of the growth factor, insulin transferring selenium. Activation of the AT2 
receptor in SK-UT-1 cells also induced apoptosis which was detectable 36 or 48 
hours post receptor stimulation. These results can be interpreted as an effort of Ang 
  
 
107
II acting on the AT2 receptor to antagonise proliferation of tumor cells, to promote 
their differentiation or to induce apoptosis.  
 
Further experiments were designed to study the signal transduction pathways 
involved in the AT2 receptor-induced differentiation of coronary endothelial cells 
(CEC) and PC12W cells. In CEC, AT2 receptor stimulation induced Zfhep mRNA 
expression. Zfhep is protein directly involved in processes associated with the cell 
differentiation. Zfhep mRNA up-regulation could only be detected when the AT1 
receptor was inhibited, demonstrating a negative-regulatory influence of AT1 
receptors on AT2-receptor mediated actions. Zfhep not only represents a suitable 
marker for the AT2 receptor-induced differentiation of CEC, but it also links the AT2 
receptor signaling and downstream events involved in the development and 
regeneration. The induction of Zfhep indicates that the AT2 receptor may play a role 
in the orchestration of intracellular events associated with embryonic development or 
differentiation. 
 
Data presented in the third part of this thesis also demonstrate that Ang II increases 
in PC12 W cells the outgrowth of medium and large neurites, which represent typical 
morphological markers of neuronal differentiation. Evidence is provided that NO is 
the mediator for the Ang II-induced cell differentiation in PC12W cells since: i) 
Inhibition of NO synthase by L-NAME, a NO synthase inhibitor, blunted the effect of 
Ang II on the differentiation, and, ii) application of sodium nitroprusside, an 
exogenous NO-donor, mimicked the morphological changes induced by AT2 receptor 
activation in these cells. The present data strongly indicate that activation of 
guanylate cyclase resulting in enhanced formation cyclic GMP (cGMP) is also 
involved in the Ang II-induced differentiation of PC12W cells. Bradykinin, similarly to 
Ang II, increased cGMP content and this effect was completely abolished after 
pretreatment with the selective B2 receptor antagonist, icatibant.  
 
These data demonstrate that Ang II, via activation of AT2 receptors, can stimulate 
cell differentiation in PC12W cells by NO-related and cGMP-dependent mechanisms. 
The results presented in this thesis identify some intracellular components of the 
signaling pathways activated by the AT2 receptor involved in the proposed function 
of this receptor in the development, regeneration and differentiation. 
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